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A B S T R A C T
Background
Globally, children under 15 years represent approximately 12% of new tuberculosis cases, but 16% of the estimated 1.4 million deaths.
This higher share of mortality highlights the urgent need to develop strategies to improve case detection in this age group and identify
children without tuberculosis disease who should be considered for tuberculosis preventive treatment. One such strategy is systematic
screening for tuberculosis in high-risk groups.
Objectives
To estimate the sensitivity and specificity of the presence of one or more tuberculosis symptoms, or symptom combinations; chest
radiography (CXR); Xpert MTB/RIF; Xpert Ultra; and combinations of these as screening tests for detecting active pulmonary childhood
tuberculosis in the following groups.
– Tuberculosis contacts, including household contacts, school contacts, and other close contacts of a person with infectious tuberculosis.
– Children living with HIV.
– Children with pneumonia.
– Other risk groups (e.g. children with a history of previous tuberculosis, malnourished children).
– Children in the general population in high tuberculosis burden settings.
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Search methods
We searched six databases, including the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase, on 14 February 2020
without language restrictions and contacted researchers in the field.
Selection criteria
Cross-sectional and cohort studies where at least 75% of children were aged under 15 years. Studies were eligible if conducted for screening
rather than diagnosing tuberculosis. Reference standards were microbiological (MRS) and composite reference standard (CRS), which may
incorporate symptoms and CXR.
Data collection and analysis
Two review authors independently extracted data and assessed study quality using QUADAS-2. We consolidated symptom screens across
included studies into groups that used similar combinations of symptoms as follows: one or more of cough, fever, or poor weight gain and
one or more of cough, fever, or decreased playfulness. For combination of symptoms, a positive screen was the presence of one or more
than one symptom.
We used a bivariate model to estimate pooled sensitivity and specificity with 95% confidence intervals (CIs) and performed analyses
separately by reference standard. We assessed certainty of evidence using GRADE.
Main results
Nineteen studies assessed the following screens: one symptom (15 studies, 10,097 participants); combinations of symptoms (12 studies,
29,889 participants); CXR (10 studies, 7146 participants); and Xpert MTB/RIF (2 studies, 787 participants). Several studies assessed more
than one screening test. No studies assessed Xpert Ultra. For 16 studies (84%), risk of bias for the reference standard domain was unclear
owing to concern about incorporation bias. Across other quality domains, risk of bias was generally low.
Symptom screen (verified by CRS)
One or more of cough, fever, or poor weight gain in tuberculosis contacts (4 studies, tuberculosis prevalence 2% to 13%): pooled sensitivity
was 89% (95% CI 52% to 98%; 113 participants; low-certainty evidence) and pooled specificity was 69% (95% CI 51% to 83%; 2582
participants; low-certainty evidence). Of 1000 children where 50 have pulmonary tuberculosis, 339 would be screen-positive, of whom 294
(87%) would not have pulmonary tuberculosis (false positives); 661 would be screen-negative, of whom five (1%) would have pulmonary
tuberculosis (false negatives).
One or more of cough, fever, or decreased playfulness in children aged under five years, inpatient or outpatient (3 studies, tuberculosis
prevalence 3% to 13%): sensitivity ranged from 64% to 76% (106 participants; moderate-certainty evidence) and specificity from 37% to
77% (2339 participants; low-certainty evidence). Of 1000 children where 50 have pulmonary tuberculosis, 251 to 636 would be screen-
positive, of whom 219 to 598 (87% to 94%) would not have pulmonary tuberculosis; 364 to 749 would be screen-negative, of whom 12 to
18 (2% to 3%) would have pulmonary tuberculosis.
One or more of cough, fever, poor weight gain, or tuberculosis close contact (World Health Organization four-symptom screen) in children
living with HIV, outpatient (2 studies, tuberculosis prevalence 3% and 8%): pooled sensitivity was 61% (95% CI 58% to 64%; 1219 screens;
moderate-certainty evidence) and pooled specificity was 94% (95% CI 86% to 98%; 201,916 screens; low-certainty evidence). Of 1000
symptom screens where 50 of the screens are on children with pulmonary tuberculosis, 88 would be screen-positive, of which 57 (65%)
would be on children who do not have pulmonary tuberculosis; 912 would be screen-negative, of which 19 (2%) would be on children who
have pulmonary tuberculosis.
CXR (verified by CRS)
CXR with any abnormality in tuberculosis contacts (8 studies, tuberculosis prevalence 2% to 25%): pooled sensitivity was 87% (95% CI 75%
to 93%; 232 participants; low-certainty evidence) and pooled specificity was 99% (95% CI 68% to 100%; 3281 participants; low-certainty
evidence). Of 1000 children, where 50 have pulmonary tuberculosis, 63 would be screen-positive, of whom 19 (30%) would not have
pulmonary tuberculosis; 937 would be screen-negative, of whom 6 (1%) would have pulmonary tuberculosis.
Xpert MTB/RIF (verified by MRS)
Xpert MTB/RIF, inpatient or outpatient (2 studies, tuberculosis prevalence 1% and 4%): sensitivity was 43% and 100% (16 participants;
very low-certainty evidence) and specificity was 99% and 100% (771 participants; moderate-certainty evidence). Of 1000 children, where
50 have pulmonary tuberculosis, 31 to 69 would be Xpert MTB/RIF-positive, of whom 9 to 19 (28% to 29%) would not have pulmonary
tuberculosis; 969 to 931 would be Xpert MTB/RIF-negative, of whom 0 to 28 (0% to 3%) would have tuberculosis.
Studies oQen assessed more symptoms than those included in the index test and symptom definitions varied. These diRerences
complicated data aggregation and may have influenced accuracy estimates. Both symptoms and CXR formed part of the CRS (incorporation
bias), which may have led to overestimation of sensitivity and specificity.
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Authors' conclusions
We found that in children who are tuberculosis contacts or living with HIV, screening tests using symptoms or CXR may be useful, but our
review is limited by design issues with the index test and incorporation bias in the reference standard.
For Xpert MTB/RIF, we found insuRicient evidence regarding screening accuracy.
Prospective evaluations of screening tests for tuberculosis in children will help clarify their use. In the meantime, screening strategies need
to be pragmatic to address the persistent gaps in prevention and case detection that exist in resource-limited settings.
P L A I N   L A N G U A G E   S U M M A R Y
Screening tests for active pulmonary tuberculosis in children
Why is improving screening for pulmonary tuberculosis in children important?
Tuberculosis is one of the leading causes of death worldwide. Most children who die from tuberculosis are never diagnosed or treated.
Screening may be useful to identify children with possible tuberculosis and refer them for further testing. As well, screening could be used
to identify children without tuberculosis, who should be considered for preventive treatment. A false-positive result means that children
may undergo unnecessary testing and treatment and may not receive preventive treatment promptly. A false-negative result means that
children have tuberculosis, but may miss further testing to confirm the diagnosis.
What is the aim of this review?
To determine the accuracy of screening tests for active pulmonary tuberculosis in children in high-risk groups, such as children with HIV
and close contacts of people with tuberculosis.
What was studied in this review?
Screening tests were: one tuberculosis symptom; one or more of a combination of tuberculosis symptoms; the World Health Organization
(WHO) four-symptom screen (one or more of cough, fever, poor weight gain, or tuberculosis contact) in children with HIV, recommended
at each healthcare visit; chest radiography (CXR); and Xpert MTB/RIF.
What are the main results in this review?
Nineteen studies assessed the following screening tests: one symptom (15 studies, 10,097 participants); more than one symptom (12
studies, 29,889 participants); CXR (10 studies, 7146 participants); and Xpert MTB/RIF (two studies, 787 participants).
Symptom screening
For every 1000 children screened, if 50 had tuberculosis according to the reference standard:
One or more of cough, fever, or poor weight gain in tuberculosis contacts (composite reference standard (CRS) (4 studies)
– 339 would screen positive, of whom 294 (87%) would not have tuberculosis (false positive).
– 661 would screen negative, of whom 5 (1%) would have tuberculosis (false negative).
One or more of cough, fever, or decreased playfulness in children under five, inpatient or outpatient (CRS) (3 studies)
– 251 to 636 would screen positive, of whom 219 to 598 (87% to 94%) would not have tuberculosis (false positive).
– 364 to 749 would screen negative, of whom 12 to 18 (2% to 3%) would have tuberculosis (false negative).
One or more of cough, fever, poor weight gain, or tuberculosis close contact (WHO four-symptom screen) in children with HIV, outpatient (CRS)
(2 studies)
– 88 would screen positive, of which 57 (65%) would not have tuberculosis (false positive).
– 912 would screen negative, of which 19 (2%) would have tuberculosis (false negative).
Abnormal CXR in tuberculosis contacts (CRS) (8 studies)
– 63 would screen positive, of whom 19 (30%) would not have tuberculosis (false positive).
– 937 would screen negative, of whom 6 (1%) would have tuberculosis (false negative).
Xpert MTB/RIF in children, inpatient or outpatient microbiologic reference standard (MRS) (2 studies)
Screening tests for active pulmonary tuberculosis in children (Review)










Cochrane Database of Systematic Reviews
– 31 to 69 would be Xpert MTB/RIF-positive, of whom 9 to 19 (28% to 29%) would not have tuberculosis (false positive).
– 969 to 931 would be Xpert MTB/RIF-negative, of whom 0 to 28 (0% to 3%) would have tuberculosis (false negative).
How reliable are the results of the studies in this review?
Diagnosing tuberculosis in children is diRicult. This may lead to screening tests appearing more or less accurate than they actually are. For
Xpert MTB/RIF, there were few studies and children tested to be confident about results.
Who do the results of this review apply to?
Children at risk for pulmonary tuberculosis. Results likely do not apply to children in the general population. Studies mainly took place in
countries with a high burden of tuberculosis.
What are the implications of this review?
In children who are tuberculosis contacts or living with HIV, screening tests using symptoms or CXR may be useful. However, symptoms and
CXR formed part of the reference standard, which may falsely elevate the accuracy of the results. We urgently need better screening tests
for tuberculosis in children to better identify children who should be considered for tuberculosis preventive treatment and to increase the
timeliness of treatment in those with tuberculosis disease.
How up-to-date is this review?
To 14 February 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Symptoms for screening of pulmonary tuberculosis
Review question: what is the accuracy of symptom groups to screen for pulmonary tuberculosis?
Studies: cross-sectional and cohort studies
Setting: inpatient and outpatient
Patients/population: children with close tuberculosis contacts
Index tests: groups of multiple symptoms
Role: an initial test
Threshold for index tests: any 1 of multiple symptoms
Reference standards: composite























False negatives 1 (0 to 2) 5 (1 to 24) 11 (2 to 48)
⊕⊕⊝⊝
Low a,b
True negatives 687 (507 to
826)
656 (485 to 789) 621 (459 to 747)








False positives 308 (169 to
488)
294 (161 to 465) 279 (153 to 441)
⊕⊕⊝⊝
Low c,d




False negatives 1 to 2 12 to 18 24 to 36
⊕⊕⊕⊝
Moderate f
True negatives 368 to 766 352 to 731 333 to 693










Specificity range 37% to
77% e
2339 (3)










































































































































































False negatives 2 (2 to 2) 19 (18 to 21) 39 (36 to 42)
⊕⊕⊕⊝
Moderate j
True negatives 935 (856 to
975)
893 (817 to 931) 846 (774 to 882)
















False positives 60 (20 to 139) 57 (19 to 133) 54 (18 to 126)
⊕⊕⊝⊝
Low j,k
CI: confidence interval; TB: tuberculosis; WHO: World Health Organization.
GRADE certainty of the evidence
High: further research is very unlikely to change our confidence in the estimate of effect.
Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low: any estimate of effect is very uncertain.
We included plausible prevalence estimates for the target condition suggested by the WHO Global Tuberculosis Programme. The upper limit for the prevalence of tuberculosis in
children in a high-risk group in a health facility in a high tuberculosis burden country was estimated to be 10% (100/1000 children); the lower limit for the prevalence of tuberculosis
in children in the general population in a high tuberculosis burden country was estimated to be 0.5% (5/1000 children).
Confidence intervals were estimated based on those around the point estimates for pooled sensitivity and specificity.
aThe two studies with relatively lower sensitivity estimates only included children younger than five years of age, which may explain in part the lower sensitivity. We downgraded
one level for inconsistency.
bThere was a low number of children with pulmonary tuberculosis contributing to this analysis for the observed sensitivity. We considered the 95% CI around false negatives
and true positives would likely lead to diRerent decisions depending on which confidence limits are assumed. As we had already downgraded for inconsistency, we downgraded
one level for imprecision.
cThe single study with notably lower specificity used a symptom screen that assessed the presence of symptoms over the past month, while the symptom screens of other studies
were composed of more recent symptoms. This may explain diRerences in specificity. We downgraded one level for inconsistency.
dWe considered the 95% CI around false positives and true negatives would likely lead to diRerent decisions depending on which confidence limits are assumed. We downgraded
one level for imprecision.
eReported as range from studies as meta-analysis did not converge and pooled estimates could not be obtained.
fThere were few participants contributing to the estimation of sensitivity. We downgraded one level for imprecision.
gThe study with notably higher specificity did not have any obvious characteristics to explain this. We downgraded one level for inconsistency.
hThe wide range around true negatives and false positives may lead to diRerent decisions depending on which limits are assumed. We downgraded one level for imprecision.
iReported as number of screens rather than participants.
jAs assessed by QUADAS-2, both studies had high risk of bias in the flow and timing domain. We downgraded one level for risk of bias.
kFor individual studies, specificity estimates ranged from 89% to 97%. We thought that diRerences in threshold for clinical diagnosis could explain in part the heterogeneity. We
downgraded one level for inconsistency.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.






































































































































































Summary of findings 2.   Chest radiography for screening of pulmonary tuberculosis
Review question: what is the accuracy of chest radiography to screen for pulmonary tuberculosis?
Studies: cross-sectional and cohort studies
Setting: inpatient and outpatient
Patients/population: children with close tuberculosis contacts
Index test: abnormal chest radiography
Role: an initial test
Threshold for index tests: author defined and implicit as utilized by the chest radiography reader
Reference standard: composite








True positives 4 (4 to 5) 44 (38 to 47) 87 (75 to 93)Pooled sensitivity 87%
(75% to 93%)
232 (8); 2% to 25%
False negatives 1 (0 to 1) 6 (3 to 12) 13 (7 to 25)
⊕⊕⊝⊝
Low a,b,c
True negatives 975 (677 to 985) 931 (646 to 941) 882 (612 to 891)Pooled specificity 99%
(68% to 100%)
3281 (8)
False positives 20 (10 to 318) 19 (9 to 304) 18 (9 to 288)
⊕⊕⊝⊝
Low a,d,e
CI: confidence interval; TB: tuberculosis.
GRADE certainty of the evidence
High: further research is very unlikely to change our confidence in the estimate of effect.
Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low: any estimate of effect is very uncertain.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy mea-
sure. These are reported in the main body of the text of the review.
Prevalence estimates were suggested by the Child and Adolescent TB Working Group. The upper limit for the prevalence of tuberculosis in children in a high-risk group in a health
facility in a high tuberculosis-burden country was estimated to be 10% (100/1000 children); the lower limit for the prevalence of tuberculosis in children in the general population
in a high tuberculosis-burden country was estimated to be 0.5% (5/1000 children).
Confidence intervals were estimated based on those around the point estimates for pooled sensitivity and specificity.




































































































































































bOne study had a low sensitivity (52%), but the other seven had sensitivity of 78% or above. The reason for the diRerence in sensitivity was unclear. We did not downgrade for
inconsistency.
cThere were relatively few children contributing to the analysis of sensitivity. We downgraded one level for imprecision.
dFor individual studies, specificity estimates ranged from 28% to 100%. Seven studies had a specificity of 73% or higher. Inter-reader variability in the interpretation of paediatric
chest radiographs could in part explain the heterogeneity. We downgraded one level for inconsistency.
eThe 95% CI around true negatives and false positives would likely lead to diRerent decisions depending on which confidence limits are assumed. However, these are also
attributable to inconsistency and have already been downgraded in that domain so we did not downgrade further for imprecision.
 
 
Summary of findings 3.   Xpert MTB/RIF for screening of pulmonary tuberculosis
Review question: what is the accuracy of Xpert MTB/RIF to screen for pulmonary tuberculosis?
Studies: cross-sectional and cohort studies
Setting: inpatient and outpatient
Patients/population: children evaluated in inpatient or outpatient settings
Index tests: Xpert MTB/RIF
Role: an initial test
Threshold for index tests: an automated result is provided
Reference standard: microbiological




Prevalence 0.5% Prevalence 5% Prevalence 10%
Certainty of the evi-
dence (GRADE)
True positives 2 to 5 22 to 50 43 to 100Sensitivities 43%
and 100%
16 (2); 1% and 4%
False negatives 0 to 3 0 to 28 0 to 57
⊕⊝⊝⊝
Very low a,b,c
True negatives 975 to 985 931 to 941 882 to 891Specificities 99%
and 100%
771 (2)
False positives 10 to 20 9 to 19 9 to 18
⊕⊕⊕⊝
Moderate b
GRADE certainty of the evidence
High: further research is very unlikely to change our confidence in the estimate of effect.
Moderate: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.




































































































































































The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy mea-
sure. These are reported in the main body of the text of the review.
We included plausible prevalence estimates for the target condition suggested by the World Health Organization Global Tuberculosis Programme. The upper limit for the
prevalence of tuberculosis in children in a high-risk group in a health facility in a high tuberculosis-burden country was estimated to be 10% (100/1000 children); the lower limit
for the prevalence of tuberculosis in children in the general population in a high tuberculosis-burden country was estimated to be 0.5% (5/1000 children).
aThe study with the higher sensitivity had only two cases included in the estimation of sensitivity. This study was also conducted in an inpatient setting evaluating children with
severe malnutrition, while the other was in an outpatient setting evaluating child tuberculosis contacts. These diRerences may have explained in part the variability in sensitivity
estimates. We downgraded one level for inconsistency.
bThere were only two studies, both conducted in Africa. Neither was a high tuberculosis-burden country. The applicability to other settings comes with some uncertainty. We
downgraded one level for indirectness.
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B A C K G R O U N D
Tuberculosis continues to elude traditional control strategies.
According to the WHO Global Tuberculosis Report 2020, an
estimated 10 million people in 2019 were ill with tuberculosis
worldwide. Of these, over 25% were not diagnosed or reported
to the World Health Organization (WHO). Children less than 15
years old represented approximately 12% of incident cases, but
16% of the estimated 1.4 million deaths from tuberculosis in
2019. This relatively higher share of mortality in children highlights
urgent needs of improved case detection and subsequent access to
treatment in this age group (WHO Global Tuberculosis Report 2020).
Case finding is a crucial step in the cascade of care for people
with tuberculosis; however, for most deaths from childhood
tuberculosis, the disease is never diagnosed (Jenkins 2017). In the
"Roadmap towards ending TB in children and adolescents," the
WHO identifies case finding for childhood tuberculosis as a key
activity (WHO 2018). Major factors that lead to underdiagnosis of
childhood tuberculosis include the following: 1. symptoms tend
to be less specific in children and overlap with those of other
common childhood diseases; 2. existing tests for children are
invasive and have suboptimal sensitivity; ideally, tests need to be
inexpensive, accessible, and usable at the point of care, allowing
for actionable information for patient care; and 3. reliance on a
clinical diagnosis of tuberculosis, without microbiological evidence
of disease, requires expertise, which is oQen not available in areas
where the burden of disease is greatest. Given these factors,
national and international guidelines for child health generally lack
systematic screening strategies for tuberculosis (WHO 2018).
For adults, systematic screening for tuberculosis in high-risk groups
and vulnerable populations is a more established strategy to
improve case detection in high-burden settings. In 2013, the WHO
published "Systematic screening for active tuberculosis: principles
and recommendations." This document provided guidance for the
development of screening approaches for adults (WHO 2013a).
One Cochrane protocol (van't Hoog 2014) and an ensuing non-
Cochrane systematic review (van't Hoog 2013) contributed to the
WHO recommendations (WHO 2013a). Participants included in
the systematic review were adults aged 15 years and older. The
review excluded studies of children aged zero to five years or
studies of childhood tuberculosis only. Since 2013, estimation
of the true burden of childhood tuberculosis has improved and
several promising strategies for case finding are being either
newly implemented or developed (Schumacher 2019; Stop TB
Partnership 2019). With this, there is a new call to push forward
systematic screening for childhood tuberculosis (Reuter 2019; WHO
2018). This review addressed tuberculosis screening strategies in
children under 15 years of age.
Screening
Tuberculosis screening is a term that has been used diRerently
in the literature depending on the context. We have adopted
the definition of tuberculosis screening from the WHO as
"the systematic identification of people with suspected active
TB [tuberculosis], in a predetermined target group, using
tests, examinations or other procedures that can be applied
rapidly" (WHO 2013a; WHO 2015). The WHO's more recent End-TB
strategy emphasizes early diagnosis of tuberculosis and systematic
screening of contacts and high-risk groups (WHO 2018), which is in
line with the above definition of tuberculosis screening.
Target condition being diagnosed
Tuberculosis is a communicable disease caused by the bacterium
Mycobacterium tuberculosis (M tuberculosis). A small fraction
of people with tuberculosis infection initially develops active
tuberculosis (tuberculosis disease). More commonly, initial
infection leads to latent tuberculosis infection, which has the
potential to become active tuberculosis throughout a person's
lifetime, especially during states of immunosuppression such as
HIV infection and malnutrition. M tuberculosis is transmitted from
person to person through the air and, therefore, most commonly
causes disease in the lungs, referred to as pulmonary tuberculosis.
Tuberculosis can, however, occur in any organ or tissue outside of
the lungs (referred to as extrapulmonary tuberculosis), with lymph
node tuberculosis as the most common form and tuberculous
meningitis as the most severe form of extrapulmonary disease.
As the most common form of active tuberculosis is lung disease,
most screening studies in adults and children evaluate tests and
strategies for pulmonary tuberculosis and verify tuberculosis using
respiratory specimens. In this review, the target condition is
pulmonary tuberculosis.
Signs and symptoms of pulmonary tuberculosis include fever,
cough, night sweats, weight loss or poor weight gain, visible neck
mass, and decreased activity. However, pulmonary tuberculosis
symptoms in children, especially those under five years of age, tend
to be less specific because they oQen overlap with other common
paediatric conditions such as pneumonia, HIV-associated lung
disease, and malnutrition (Jaganath 2012; Oliwa 2015). Compared
to adults, children are much more likely to progress from latent
tuberculosis infection to tuberculosis disease. Further, among
those progressing to disease, younger children are more likely to
experience severe manifestations (Marais 2004; Perez-Velez 2012).
Microbiological confirmation of pulmonary tuberculosis in children
is complicated by two main factors. First, younger children are
not able to voluntarily expectorate sputum, which is the standard
specimen used for microbiological detection of pulmonary
tuberculosis in adults. Therefore, specimens from young children
traditionally are collected from more invasive methods such as
gastric aspiration and sputum induction (Graham 2015). Second,
lung cavities with high bacillary load as seen in pulmonary
tuberculosis in adults are uncommon in children, especially in
young children under 10 years of age. The number of bacilli causing
disease in children tends to be low and the 'paucibacillary' nature
of their disease compromises diagnostic yield (Dunn 2016).
Index test(s)
This review included the following index tests used in screening for
pulmonary childhood tuberculosis: symptoms, chest radiography
(CXR), Xpert MTB/RIF and Xpert Ultra, and various combinations of
these tests.
With symptom-based screening, individuals or their caregivers
are interviewed about symptoms suggestive of pulmonary
tuberculosis such as cough or fever of varying duration, weight
loss, poor weight gain or reduced appetite, and decreased physical
activity. Though not a true symptom, recent contact with an
infectious person with tuberculosis is another important factor
when interviewing for tuberculosis risk (Graham 2015).
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CXR may involve posterior-anterior, anterior-posterior, or lateral
recording, or a combination of these. Commonly used types of
CXR include conventional CXR (producing 36 cm × 43 cm film),
digital radiography, and computed radiography. The most common
radiographic finding of pulmonary childhood tuberculosis is
hilar lymphadenopathy (Leung 1992), though CXR has limitations
identifying this finding (Swingler 2005). Accurate interpretation of
CXR findings for pulmonary childhood tuberculosis is dependent
on the ability of the healthcare professional interpreting the CXR,
and wide interobserver variation has been reported (Du Toit
2002; Kaguthi 2014). Computer-aided interpretation of CXR for
pulmonary tuberculosis diagnosis or screening is a promising new
technology (Qin 2019; Sodhi 2017) that has been recommended
by the WHO as an alternative to human reader interpretation
of CXR screening and triage for tuberculosis in people aged 15
years and above (WHO Consolidated Guidelines (Module 2) 2021).
However, it has not been adequately assessed in children and
may be complicated by the wide variety of intra-thoracic disease
manifestations observed in children compared to adults (Reuter
2019).
Xpert MTB/RIF and Xpert Ultra, the newest version (Cepheid Inc,
CA, USA) are nucleic acid amplification tests (NAATs) that can
detect both M tuberculosis DNA and rifampicin resistance. We did
not assess rifampicin resistance in this review. These two assays
are completely automated and self-contained once the sample is
loaded into the cartridge. Specimen processing is similar for both
Xpert MTB/RIF and Xpert Ultra using Xpert Sample Reagent and
requires 15 minutes of incubation. Within two hours, results are
available. A consistent supply of electricity, temperature control,
and annual calibration of the cartridge modules are needed (Global
Laboratory Initiative 2019). Xpert Ultra has approximately 1-log
improvement in the lower limit of detection of bacterial load
compared to Xpert MTB/RIF (Chakravorty 2017). Xpert Ultra also
has a new result category, 'trace call,' that represents minimally
detectable bacillary load. According to the WHO, a 'trace call'
result is adequate to prompt initiation of tuberculosis treatment
in children or people living with HIV (WHO 2017b). The WHO
recommends the use of Xpert MTB/RIF and Xpert Ultra as initial
diagnostic tests for pulmonary tuberculosis in adults and children.
Specifically in children, the guidelines recommend a variety of
specimen types for diagnosis of pulmonary tuberculosis, including
gastric aspirates, nasopharyngeal aspirates, and stool specimens,
in addition to sputum (WHO Consolidated Guidelines (Module 3)
2020). We included Xpert MTB/RIF (all versions) and Xpert Ultra in
this review.
Another WHO-recommended NAAT for detection of tuberculosis
is Truenat MTB and Truenat MTB Plus (Molbio Diagnostics/
Bigtec Labs, Goa/Bengaluru, India) (WHO Consolidated Guidelines
(Module 3) 2020). However, to our knowledge, there are currently
no published studies assessing this test in children.
Clinical pathway
As shown in Figure 1, there are two complementary approaches
to detection of tuberculosis disease. The first is the patient-
initiated pathway, also known as passive case finding. The second
is the provider-initiated screening or active case finding pathway
(WHO 2015), which is the analytic framework for this review.
One major challenge with either pathway is that 'high-quality
diagnosis' is elusive for childhood tuberculosis, especially for
younger children and children in resource-limited settings. This
diagram also demonstrates the wide range of potential target
populations for childhood tuberculosis screening, ranging from
contacts of those with tuberculosis ('exposed') to symptomatic
children in inpatient or outpatient settings (e.g. children living with
HIV, as described below). This review included evidence from all
these systematic screening strategies.
 
Figure 1.   There are two complementary approaches to detection of tuberculosis (TB) disease. The first is the
patient-initiated pathway, also known as passive case finding. The second is the provider-initiated screening
pathway (WHO 2015), which is the analytic framework for this review. One major challenge with either pathway is
that 'high-quality diagnosis' is elusive for child tuberculosis, especially for younger children and in resource-limited
settings. This diagram also demonstrates the wide range of potential target populations for tuberculosis screening,
ranging from contacts of those with tuberculosis ('exposed') to symptomatic patients accessing healthcare, such as
children living with HIV. Copyright © [2015] [World Health Organization]: reproduced with permission.
 
There is no standard screening approach for children, but for the
subgroup of children living with HIV, since 2011 the WHO has
recommended routine symptom-based screening for all children
living with HIV presenting to healthcare facilities as part of the
intensified case-finding strategy. Under this guideline, children
living with HIV over 12 months of age who report any cough,
fever, weight loss or poor weight gain, or history of recent contact
with someone with tuberculosis should be further investigated
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for tuberculosis. If no symptoms or recent tuberculosis contact
are reported they are considered "unlikely to have active TB."
Although this 'strong recommendation' was based upon 'low-
quality evidence' (WHO 2011), it exemplifies a standardized
screening approach for tuberculosis. A similar symptom-based
approach has been suggested for household contacts of infectious
tuberculosis cases, focusing on any current symptoms (WHO 2014).
The main aim here is to allow tuberculosis contacts or children
living with HIV, who are completely asymptomatic, prompt access
to tuberculosis preventive treatment. For tuberculosis contacts, the
WHO Consolidated Guidelines (Module 1) 2020 make a distinction
in the strength of recommendation for provision of tuberculosis
preventive treatment in children aged under five years (strong
recommendation) and in children aged five years and older
(conditional recommendation).
Screening may use sequential or parallel strategies (Figure 2).
With sequential strategies, only those with a positive result in the
first step are screened in the second step. With parallel screening
strategies, multiple diRerent screens are done initially, and any
positive screen or combinations of positive screens prompts further
investigation (i.e. confirmatory test) for the target condition. We
included results from various screening strategies in this review.
We considered individuals' results to be 'true screen positives' if
they were rightfully referred for confirmatory testing; in contrast,
we considered individuals' results to be 'false screen positives'
if the individuals were referred for confirmatory testing but not
diagnosed with tuberculosis. Although individuals with negative
screens should not undergo confirmatory testing during routine
clinical practice, individuals with negative screens may complete
confirmatory testing in a research context to establish true screen
negatives and false screen negatives. As described in Types of
studies, studies that only conducted confirmatory testing on those
with positive screens were excluded in this review. In the context of
this review, the intended use of the index tests is considered to be
'screening,' and their role is considered to be triage tests. With triage
tests, the index test is used prior to an existing test or strategy, and
only those with a specific result on the triage test continue along
the clinical pathway (Bossuyt 2006).
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Figure 2.   DiMerent screening and diagnostic algorithms.
 
The downstream consequences of screening include the following.
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• True positive: children would benefit from rapid diagnosis and
initiation of appropriate treatment.
• True negative: children would be spared unnecessary treatment
and would benefit from reassurance, pursuit of an alternative
diagnosis if they have symptoms, and prompt initiation of
tuberculosis preventive treatment if eligible.
• False positive: children would probably experience anxiety and
morbidity caused by additional testing, unnecessary treatment,
and possible adverse events; strain on healthcare resources with
unnecessary additional testing and treatment; possible stigma
associated with a tuberculosis diagnosis; the chance that a false-
positive result may halt further diagnostic evaluation of the
true underlying condition; and missed or delayed initiation of
tuberculosis preventive treatment if eligible.
• False negative: children would experience an increased risk
of morbidity and mortality, and delayed or inappropriate
treatment initiation; there would be risk of ongoing tuberculosis
transmission particularly in older children; and they may be
inappropriately initiated on tuberculosis preventive treatment.
Alternative test(s)
Two types of immunological tests excluded from this review are
the tuberculin skin test (TST) and the interferon gamma release
assay (IGRA). Both methods are dependent on the cellular immune
response to M tuberculosis antigens in individuals previously
exposed to the organism, and neither can distinguish between
latent tuberculosis infection and active tuberculosis disease (Pai
2014). Further, neither method is sensitive enough to serve as a
rule out test for tuberculosis disease in children, but is mainly
used to confirm tuberculosis infection and to support clinical
decision making; with full consideration of all the stated caveats.
The TST has been in clinical use for over a century and involves
intradermal injection of M tuberculosis purified protein derivative.
Drawbacks to the TST include the need for a second clinical
encounter 48 to 72 hours aQer placement for result interpretation,
inter-reader variability, a tendency for previous bacillus Calmette-
Guerin vaccination to result in false-positive results, and a tendency
for false-negative results in immunosuppressed individuals or due
to anergy in individuals with active disease (Pai 2014).
Commercially available IGRAs include QuantiFERON-TB Gold In-
tube (QFT-GIT; Qiagen, Germantown, MD), QuantiFERON-TB Gold
Plus (QFT-Plus; Qiagen), and T-SPOT.TB (Oxford Immunotec Ltd,
Oxford, UK). To improve upon the TST, IGRAs were developed to
measure release of interferon gamma from T cells stimulated by
antigens specific to M tuberculosis. The QFT-GIT assay stimulates
interferon gamma release from CD4+ T cells, while the QFT-Plus
assay can stimulate both CD4+ and CD8+ T-cell responses. CD8+
cytotoxic T cells have been shown to have higher responses in
people with active pulmonary tuberculosis compared to those with
latent tuberculosis infection (Day 2011; Rozot 2013). Individuals
with low CD4+ T-cell counts (e.g. those with advanced HIV) have
been shown to maintain CD8+ T-cell antigen responses to M
tuberculosis (Sutherland 2010). For these reasons, it is theorized
that the QFT-Plus assay may be more sensitive for people living
with HIV and those with active tuberculosis (Theel 2018), although
this has not been demonstrated in clinical practice. The T-SPOT.TB
is an enzyme-linked immunoassay that involves incubation of
peripheral blood mononuclear cells with antigens specific to M
tuberculosis. If the number of interferon gamma-producing T cells
(spot-forming cells) exceeds a specific threshold relative to negative
control wells, the result is positive. All IGRAs utilize positive and
negative controls, and they can have indeterminate results if there
is a low interferon gamma response in the positive control or if there
is a high response in the negative control (Pai 2014).
Beyond the index tests described above, there are several
alternative approaches that could be used for screening or
diagnosis. This includes examination of sputum smears for acid-
fast bacilli under a light microscope using the classical Ziehl-
Neelsen staining technique, or fluorescence microscopy with newer
light-emitting diode (LED) microscopy. One review found that
in children, the sensitivity of smear microscopy was around
22% in gastric aspirates and around 29% in expectorated and
induced sputum specimens (WHO 2013b). Microscopy is unable
to diRerentiate M tuberculosis from nontuberculous mycobacteria,
which may also cause lung disease.
New assays detect lipoarabinomannan (LAM) antigen in the urine
of people with tuberculosis disease. LAM is a lipopolysaccharide
present in the lipid rich mycobacterial cell wall. Urinary lateral
flow LAM assays have the advantages of being rapid and non-
invasive. Currently, the only commercially available lateral flow
LAM assay is the Alere Determine TB LAM Ag (AlereLAM, Abbott,
Chicago, IL, USA). Based on evidence from randomized trials and
a Cochrane Review (Bjerrum 2019), the WHO recommends that
lateral flow LAM should be used to assist in the diagnosis of active
tuberculosis in HIV-positive adults, adolescents, and children. The
full recommendations, which diRer for inpatients and outpatients,
are described in WHO Consolidated Guidelines (Module 3) 2020.
Another LAM assay expected to become commercially available
is the Fujifilm SILVAMP TB-LAM (Fujifilm, Tokyo, Japan). Early
evidence for this assay demonstrates superior sensitivity compared
to AlereLAM for adults living with HIV (Bjerrum 2020; Broger 2020).
However, accuracy comparisons between these two LAM assays
have varied in children (Nicol 2021; Nkereuwem 2021).
The development of novel tools for detection of tuberculosis
disease is an active field. Noteworthy tests with emerging evidence
include C-reactive protein (Albuquerque 2019), IP-10 (Alsleben
2011; Holm 2014; Jenum 2016; Sudbury 2019; Tebruegge 2015),
and C-Tb (Statens Serum Institut, Copenhagen) (Aggerbeck 2019;
Ruhwald 2017). During the 2020s, more eRicient technologies
are anticipated with the hope that these will advance screening
strategies and reduce the burden of childhood tuberculosis
worldwide (Schumacher 2019; Stop TB Partnership 2019; WHO
2017a).
Rationale
ERective screening for childhood tuberculosis supports timely and
reliable diagnosis, which is essential for reducing tuberculosis-
attributable morbidity and mortality. ERective screening also
supports disease rule out, thereby guiding treatment for
latent tuberculosis infection and consideration for preventive
treatment for exposed children or other high-risk groups such as
children living with HIV. Historically, screening children for active
tuberculosis has been limited by the lack of accurate screening and
diagnostic tools. Therefore, systematic screening in children has
only been performed within specific populations with increased
risk of disease to limit the risk of false-positive test results and
consequent overtreatment of tuberculosis. Guidance from the
WHO states that "only children who are close contacts of someone
with pulmonary tuberculosis and HIV-positive children should
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be systematically screened for TB [tuberculosis]" (WHO 2015).
Optimal screening strategies for these two high-risk groups are
lacking (Szkwarko 2017), although a symptom-based approach
has been supported in resource-limited settings (WHO 2014).
Limiting systematic screening to child contacts and HIV-positive
children may propagate missed opportunities as evidence has
identified other high-risk groups of children in certain settings
and with health conditions, such as malnutrition or pneumonia,
who are also at risk of tuberculosis (Arscott-Mills 2014; Chisti
2014; LaCourse 2014; Munthali 2017; Oliwa 2015). Evidence also
demonstrates that children in tuberculosis-endemic settings have
considerable risk of tuberculosis exposure outside of their homes
(Martinez 2019). However, the unfortunate reality is that systematic
screening is rarely implemented in resource-limited settings, even
in highly vulnerable young children who are household contacts
of infectious tuberculosis cases and at high risk of tuberculosis
infection.
This Cochrane Review informed a WHO guideline Development
Group meeting convened to update recommendations for
systematic screening for active tuberculosis (WHO Consolidated
Guidelines (Module 2) 2021). To our knowledge, this is the first
systemic review on this topic in children. There have been several
systematic reviews evaluating the accuracy of the index tests
described above for the diagnosis of active tuberculosis, including
a recent Cochrane Review evaluating Xpert MTB/RIF and Xpert
Ultra in children (Kay 2020). The lack of knowledge regarding the
performance of these tests to complete childhood tuberculosis
screening reflects the diRiculty of tuberculosis research in children
and the predominance of research focused on diagnosis rather
than screening. The current review elucidates the potential of these
tools for systematic screening for active pulmonary childhood
tuberculosis in specific high-risk populations.
O B J E C T I V E S
To estimate the sensitivity and specificity of the presence of one
or more tuberculosis symptoms, or symptom combinations; chest
radiography (CXR); Xpert MTB/RIF; Xpert Ultra; and combinations of
these as screening tests for detecting active pulmonary childhood
tuberculosis in the following groups.
• Tuberculosis contacts, including household contacts, school
contacts, and other close contacts of a person with infectious
tuberculosis.
• Children living with HIV.
• Children with pneumonia.
• Other risk groups (e.g. children with a history of previous
tuberculosis, malnourished children).
• Children in the general population in high tuberculosis burden
settings.
Secondary objectives
To compare the accuracy of the diRerent index tests and diRerent
thresholds (e.g. CXR with any abnormality versus, more specifically,
CXR with abnormality suggestive of tuberculosis).
To investigate potential sources of heterogeneity in accuracy
estimates in relation to age group, HIV status, whether the study
was conducted in a high tuberculosis burden country, whether the
child received a single screening or more than one screening, and
type and number of CXR interpreters.
We were interested in the accuracy of the index tests in any setting
(i.e. community, outpatient, and inpatient).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional studies and cohort studies that
assessed the accuracy of at least one of the index tests for
pulmonary tuberculosis. We also planned to include randomized
controlled trials, but none were identified for inclusion. We
included studies from all settings and time periods. Data on the
results of index test(s) against the reference standard(s) must
have been available so that we could construct 2×2 contingency
tables containing the number of true positives, false positives,
true negatives, and false negatives. We excluded studies in which
children with negative screening test results were not verified by
the reference standard because true-negative and false-negative
test results cannot be obtained. Studies applying index tests
multiple times to an individual within a short timeframe (e.g. within
a single hospital admission) were considered diagnostic rather than
using a screening approach, and we excluded these studies.
We included cohort studies with children with active tuberculosis
identified aQer the time point that the screening test was applied.
Especially with studies performed in settings of intended use, the
collection of specimens and conduct of the reference standard may
occur sometime aQer the screening test was done. In low-resource
settings, this process may take weeks. However, a longer time
between the index test and the reference standard would make us
less confident that the target condition did not change between the
two tests. We addressed this issue in the QUADAS-2 flow and timing
domain and in a sensitivity analysis (see Sensitivity analyses).
We included studies that assessed more than one screening test.
We excluded case reports and case-control studies, the latter
because of the high risk of bias in diagnostic accuracy studies
(Rutjes 2006).
Participants
We included studies enrolling HIV-positive and HIV-negative
children not known to have active tuberculosis prior to screening.
We excluded studies if they did not provide data exclusive to
participants under 20 years of age with at least 75% participants
under 15 years of age. We included children in the general
population in high-burden settings and high-risk groups, including
children younger than five years old; children living with HIV;
children with recent exposure to a person with active tuberculosis;
and household, school, or other contacts of a person with active
tuberculosis. We included studies in which children were screened
only once and studies that reported longitudinal screening with
repeated screening tests at predetermined intervals.
Index tests
For symptom-based screening, we included studies that assessed
any symptom or combinations of symptoms suggestive of possible
tuberculosis, as described by the primary study authors. Symptoms
of childhood tuberculosis may include cough, fever, night sweats,
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decreased appetite, weight loss or failure to thrive, and fatigue
or reduced playfulness. Children over 10 years of age experience
symptoms similar to those recorded in adults, which may also
include haemoptysis. The threshold was presence or absence of
symptoms, as defined by the primary study authors. In addition,
we included the WHO-recommended intensified case finding (ICF)
symptom screen (current cough, fever, poor weight gain, or
tuberculosis contact for children; current cough, weight loss, night
sweats, or fever for adolescents) for HIV-infected children, applied
at each healthcare visit (WHO 2011).
For CXR screening, we included studies that utilized conventional
radiography, digital radiography, and computed radiography.
We included all classification systems for identification of CXR
abnormalities. We categorized all CXR screening results as follows.
We used an author defined threshold for CXR results. Essentially
this is an implicit threshold utilized by the CXR reader.
• Normal.
• Any CXR abnormality (i.e. abnormalities suggestive of
tuberculosis and other abnormalities).
• Abnormalities suggestive of tuberculosis.
For Xpert MTB/RIF and Xpert Ultra, we included studies in which
the index tests were evaluated in expectorated or induced sputum,
gastric aspirate specimens, nasopharyngeal aspirate specimens,
and bronchoalveolar lavage specimens. Tuberculosis bacilli in
sputum can be swallowed and detected in stool so we also included
studies assessing stool specimens. We included studies assessing
more than one type of respiratory specimen collected at the same
time and extracted 2×2 data separately for each specimen type.
Xpert MTB/RIF and Xpert Ultra provide the following printed test
results:
• MTB (M tuberculosis) DETECTED; RIF (rifampicin) resistance
DETECTED;
• MTB DETECTED; RIF resistance NOT DETECTED;
• MTB DETECTED; RIF resistance INDETERMINATE;
• MTB NOT DETECTED;
• INVALID (the presence or absence of MTB cannot be
determined);
• ERROR (the presence or absence of MTB cannot be determined);
• NO RESULT (the presence or absence of MTB cannot be
determined).
Xpert Ultra also gives the following semi-quantitative
classifications of M tuberculosis bacterial burden from the sample:
trace, very low, low, moderate, and high. For this review, Xpert MTB/
RIF and Xpert Ultra results were categorized as:
• positive: 'MTB DETECTED,' including 'trace' results from Xpert
Ultra;
• negative: 'MTB NOT DETECTED;'
• inconclusive: 'INVALID,' 'ERROR,' or 'NO RESULT.'
We did not evaluate detection of rifampicin resistance in this review.
As shown in Figure 2, with two parallel screening tests, the parallel
strategy will entail any of the individual components of the strategy
being positive resulting in a positive parallel strategy screen and
all individual components being negative resulting in a negative
parallel strategy screen. For studies assessing parallel screening
tests, if data for the individual components of the parallel strategy
against the reference standard were also available, these data were
also extracted for analysis.
Target conditions
The target condition was active pulmonary tuberculosis.
We anticipated that some studies may have evaluated the index
tests for active tuberculosis and not explicitly stated 'pulmonary
tuberculosis,' the target condition in this review. We included these
studies because the most common type of active tuberculosis in
children is pulmonary disease; hence, most screening studies in
children evaluate tests for pulmonary tuberculosis and diagnose
tuberculosis using respiratory specimens.
Reference standards
We used two reference standards, a microbiological and a
composite reference standard.
Microbiological reference standard
Confirmed pulmonary tuberculosis was defined as a positive
culture (on solid or liquid medium) or a positive Xpert MTB/RIF or
Xpert Ultra test from a respiratory specimen. When Xpert MTB/RIF
was the index test, we excluded it from the reference standard to
avoid incorporation bias. We did not include studies where sputum
smear microscopy was the reference standard.
Collection of multiple respiratory specimens may improve the
diagnostic yield of testing for childhood tuberculosis (Cruz 2012;
Zar 2012). With respect to the microbiological reference standard,
we included studies that involved multiple specimens collected
over time. In these studies, we used the classification of the
reference standard as defined by the primary study authors (most
commonly at least one positive result representing a positive
reference test).
Composite reference standard
Confirmed pulmonary tuberculosis was defined as microbiological
confirmation (as above in 'Microbiological reference standard')
or author-defined clinical pulmonary tuberculosis. Clinical
pulmonary tuberculosis must have included a component of
follow-up to help verify or rule out the diagnosis of active
tuberculosis. Hence, the composite reference standard was used
to verify disease-positive results and disease-negative results. The
consensus research definition for clinical childhood tuberculosis
for diagnostic studies was considered too restrictive for the purpose
of this review (Graham 2015).
'Not tuberculosis' was defined as negative microbiological test
results and establishment of alternative diagnosis during the
evaluation for tuberculosis, resolution of symptoms without
tuberculosis treatment, or no progression of symptoms for at least
one month without tuberculosis treatment.
Two of our index tests, symptoms and CXR, are typically
components of case definitions used to support the clinical
diagnosis of tuberculosis (i.e. not microbiologically confirmed).
This raised the potential for incorporation bias with the composite
reference standard, that is, where the result of the index test is
used to help determine the reference standard result. We assessed
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the composite reference standard for incorporation bias using
the QUADAS-2 signalling question: "Were the reference standard
results interpreted without knowledge of the results of the index
test?" In addition, we discussed incorporation bias as a limitation
of the review.
Search methods for identification of studies
We attempted to identify all relevant published studies regardless
of language. Although they were not assessed as index tests in
this review, we included immunological tests (TST and IGRA) in the
search strategy. This will allow for archiving of relevant studies for
a future systematic review assessing immunological tests as index
tests.
Electronic searches
We searched the following databases without language restriction
up to 14 February 2020, using the search terms and strategy
described in Appendix 1.
• Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library.
• MEDLINE and MEDLINE in Process (Ovid), from 1946.
• Embase (Ovid), from 1947.
• Scopus (Elsevier) from 1970.
We also searched ClinicalTrials.gov, the WHO International Clinical
Trials Registry Platform (ICTRP; www.who.int/trialsearch), and
the International Standard Randomized Controlled Trials Number
(ISRCTN) registry (www.isrctn.com/) for trials in progress.
Searching other resources
To identify any relevant published data not identified with our
electronic search, we contacted experts in the field of childhood
tuberculosis and checked the references of relevant reviews from
the past 10 years. With the studies selected for inclusion in this
review, we performed forward and backward reference checking to
identify any additional eligible studies.
Data collection and analysis
Selection of studies
We used Covidence to manage the selection of studies (Covidence).
Two review authors (BV and TN) independently screened all
titles and abstracts from the electronic searches to identify
potentially eligible studies. We obtained full-text articles of
potentially eligible studies, and the two review authors (BV and
TN) independently assessed them for study eligibility using the
predefined inclusion and exclusion criteria. We resolved any
disagreements by discussion or with a third review author (AMM or
KRS). As needed, we contacted study authors to clarify the study
methods and other information. Studies excluded during the full-
text review are listed in Characteristics of excluded studies with
reasons for exclusion. We illustrated the study selection process in
a PRISMA flow diagram (Moher 2009).
Data extraction and management
We designed a data extraction form and piloted it on two included
studies. AQer reviewing the piloted forms with the other review
authors, we finalized the form. Two review authors independently
used the data extraction form to extract data from the included
studies (BV, TN, AMM, or KRS). We discussed any inconsistencies
with a third review author. We entered the extracted data into
an Excel database on password-protected computers (Excel 2013).
Data will be secured to the Cochrane Infectious Diseases Group's
'Archive' drives for future access and review updates.
We extracted the following information from each included study.
Study details
• First author, title, year of publication, journal, language.
• Study design, sampling method, prospective/retrospective, and
inclusion criteria for presumptive tuberculosis (if any).
• Number of participants aQer screening for exclusion and
inclusion criteria.
• Number of children included in the primary study analysis.
• Single or initial screening versus more than one screening in the
population.
• Any sequential or parallel screening strategies.
Participant characteristics and setting
• Description of study population.
• Age: median, mean, range, and disaggregation into categories (0
to 4 years, 5 to 14 years).
• Gender.
• HIV status.
• Proportion with severe wasting or severe acute malnutrition.
• Screening location: community, outpatient facility, or inpatient
facility.
• Children with prior tuberculosis included, yes/no? If yes, what
proportion?
• Country/countries where study was conducted.
• Country WHO classification for tuberculosis high-burden
country (WHO Global Tuberculosis Report 2020).
• Years of data collection.
Index test
• Definition of positive symptom screen.
• Symptoms assessed.
• Details of timing of contact history (i.e. current, within past year,
beyond one year).
• Types of CXR used.
• Description of radiographic findings classification.
• Type of CXR reader: radiologist, pulmonologist, general medical
oRicer, clinical oRicer, nurse, other.
• Types of respiratory specimens used.
• Types of NAATs used.
• For each index test, number of results that were true positive,
false positive, true negative, false negative, inconclusive, and
missing.
Reference standard
• Microbiological reference standard used: solid culture, liquid
culture, Xpert MTB/RIF, or Xpert Ultra.
• Criteria used for composite reference standard.
• Number of microbiological tests used to exclude tuberculosis.
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• Number of contaminated cultures and total number of cultures
performed.
• Time between the index test and the reference standard.
We followed Cochrane policy, which states that "authors of primary
studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the
interpretation against the study report and any available study
registration details or protocol."
Assessment of methodological quality
Two review authors (of BV, TN, AMM, or KRS) independently
assessed the methodological quality of the included studies using
the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2)
tool, which we adapted for this review (Whiting 2011). The tool
with signalling questions tailored to this review is in Appendix 2.
As recommended, we assessed each of the four domains (patient
selection, index test, reference standard, and flow and timing) for
risk of bias and the first three domains for concerns regarding
applicability.
We judged each item as 'yes' (adequately addressed),
'no' (inadequately addressed), or 'unclear' when there was
insuRicient information reported to make an assessment. One
review author piloted the tool on two included studies. We
then made revisions to finalize the QUADAS-2 tool, with specific
revisions as described in the DiRerences between protocol and
review section. We resolved disagreements between the two
review authors' independent assessments through discussion or
additional input from a third review author. We presented results of
the quality assessment in text, tables, and graphs.
Statistical analysis and data synthesis
We presented individual study estimates of sensitivity and
specificity graphically on forest plots and in receiver operating
characteristics (ROC) space using Review Manager 5 (Review
Manager 2020).
We considered one index test result per child per time point.
However, for studies assessing serial screening over time for
individuals, separate screens were assessed if they were also
compared against serial confirmatory tests over time (i.e.
multiple screens for one individual). In other words, in situations
where serial screening of children at each healthcare visit was
recommended, screening results (typically multiple per individual)
were used as the unit of analysis rather than single results per
participant, as with the other analyses here. Within each group
listed in Objectives, we performed analyses by index test and
reference standard. For symptom screening as the index test, we
performed analyses for single and multiple symptoms where data
were available. We consolidated symptom screens across included
studies into groups that used similar combinations of symptoms as
follows: one or more of cough, fever, or poor weight gain and one or
more of cough, fever, or decreased playfulness. For combination of
symptoms, a positive screen was the presence of one or more than
one symptom.
We combined categories depending on the number of studies and
screening definitions found in each category. We also stratified the
analyses by the type of reference standard used, microbiological or
composite.
When there were suRicient data, we performed meta-analyses to
estimate summary values of sensitivity and specificity using a
bivariate model (Chu 2006; Reitsma 2005). We chose the bivariate
model because test results were binary (present/absent), studies
used the same threshold or thresholds recommended by the test
manufacturer. When we were unable to fit a bivariate model
due to sparse data or few studies, we simplified the models to
univariate random-eRects or fixed-eRect logistic regression models
(depending on whether or not heterogeneity was observed on
forest and summary ROC (SROC) plots) to pool sensitivity and
specificity separately (Takwoingi 2015). If there were only two or
three studies available for an analysis and there was substantial
heterogeneity, we did not perform a meta-analysis. We performed
meta-analyses using the meqrlogit command in Stata version 16
(Stata).
Owing to limited data, we did not perform test comparisons.
Approach to inconclusive index test results
As described above in Index tests, the NAAT assays assessed in this
review as index tests may have inconclusive results. We planned to
report the proportion of inconclusive index test results as available,
but none of the included studies reported inconclusive results.
Investigations of heterogeneity
We visually inspected forest plots and SROC plots for heterogeneity.
We summarized descriptively the type and number of CXR
interpreters. We had planned to assess potential sources of
heterogeneity using subgroup analyses and bivariate meta-
regression. However, owing to limited data, we did not perform
subgroup analyses.
Sensitivity analyses
Owing to limited data we were unable to perform sensitivity
analyses to explore the eRect of potential sources of bias and study
design characteristics on the accuracy of the index tests.
Assessment of reporting bias
We did not formally assess reporting bias using funnel plots or
regression tests as these have not been reported as helpful for
diagnostic test accuracy studies (Macaskill 2010).
Assessment of certainty of the evidence
We assessed the certainty of evidence using the GRADE approach
for diagnostic studies (Balshem 2011; Schünemann 2008). As
recommended, we rated the certainty of evidence as high
(not downgraded), moderate (downgraded by one level), low
(downgraded by two levels), or very low (downgraded by
more than two levels) based on five domains: risk of bias,
indirectness, inconsistency, imprecision, and publication bias. For
each outcome, the certainty of evidence started as high when there
were high-quality observational studies (cross-sectional or cohort
studies) that enrolled participants with diagnostic uncertainty. If
we found a reason for downgrading, we used our judgement to
classify the reason as either serious (downgraded by one level) or
very serious (downgraded by two levels).
Four review authors (BV, TN, AMM, and KRS) discussed judgements
and applied GRADE in the following way (Schünemann 2020a;
Schünemann 2020b).
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Assessment of risk of bias
We used QUADAS-2 to assess risk of bias.
Indirectness
We assessed indirectness in relation to the population (including
disease spectrum), setting, interventions, and outcomes (accuracy
measures). We also used tuberculosis prevalence as a guide to
whether there was indirectness in the population.
Inconsistency
GRADE recommends downgrading for unexplained inconsistency
in sensitivity and specificity estimates. We prespecified analyses to
investigate potential sources of heterogeneity; however, owing to
limited data, we did not perform these. We downgraded when we
could not explain inconsistency in the accuracy estimates based
on whether the individual point estimates were similar and if the
confidence intervals overlapped in the forest plots.
Imprecision
We considered a precise estimate to be one that would allow a
clinically meaningful decision. We considered the width of the
confidence interval (CI), and asked, “Would we make a diRerent
decision if the lower or upper boundary of the CI represented
the truth?” In addition, we worked out projected ranges for true
positive, false negative, true negative, and false positive for a given
prevalence of tuberculosis and made judgements on imprecision
from these calculations.
Publication bias
We rated publication bias as undetected (not serious) for several
reasons, including the comprehensiveness of the literature search
and extensive outreach to tuberculosis researchers to identify
studies.
R E S U L T S
Results of the search
We identified and screened 2135 records for inclusion in this review.
Of these, we assessed 610 full-text papers against our inclusion
criteria. We excluded 598 papers for the following reasons: data not
available for age groups of interest (233 papers), no eligible index
tests (207 papers), full text not available (65 papers), ineligible study
design (51 papers), no eligible reference test (33 papers), diagnostic
(rather than screening) study (six papers), duplicate (two papers),
and wrong outcomes (one paper).
We identified 19 unique studies that met the inclusion criteria
of this review, 12 from the database search and seven that
were recommended from a community of paediatric tuberculosis
experts that we contacted (Aggerbeck 2018; Birungi 2018; Clemente
2017; Dreesman 2017; Jaganath 2013; Kruk 2008; LaCourse 2014;
PERCH 2019; Portevin 2014; Rose 2012; Sawry 2018; Schwoebel
2020; Tieu 2014; Togun 2015; Togun 2016; Triasih 2015a; Triasih
2015b; Ustero 2017; Vonasek 2021). All included studies were
written in English. Togun 2015 and Togun 2016 assessed diRerent
index tests in the same children, and we considered these to
be two diRerent studies. Similarly, Triasih 2015a and Triasih
2015b assessed diRerent index tests in the same children, and
we designated these as two diRerent studies. We performed
descriptive analyses of the included studies and presented their key
characteristics in the Characteristics of included studies table and
Table 1.
Figure 3 shows the flow of studies through the review process. We
listed selected excluded studies and the reasons for their exclusion
in the Characteristics of excluded studies table. These studies were
selected based upon their relevance to screening for childhood
tuberculosis despite not fulfilling inclusion criteria for this review.
The full list of excluded studies and the reasons for ineligibility is
available from the first author.
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Figure 3.   Study flow diagram.
 
Methodological quality of included studies
Figure 4 and Figure 5 show risk of bias and applicability concerns for
19 studies evaluating symptoms, CXR, and Xpert MTB/RIF to screen
for pulmonary tuberculosis.
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Figure 4.   Risk of bias and applicability concerns graph: review authors' judgements about each domain presented
as percentages across included studies.
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Figure 5.   Risk of bias and applicability concerns summary: review authors' judgements about each domain for each
included study.
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In the patient selection domain, we considered 18 studies (95%)
at low risk of bias because the studies enrolled a consecutive or
random sample of eligible participants and avoided inappropriate
exclusions. We considered one study at unclear risk of bias
because it was unclear if there was a consecutive or random
sample of eligible participants in the study (Jaganath 2013). With
respect to applicability, we considered 15 studies at low concern
because participants in these studies resembled a population that
would typically be considered for screening for tuberculosis. We
considered one study to have high concern because enrolment
criteria were stricter than is typical for selecting individuals to be
screened for tuberculosis (Portevin 2014). We considered three
studies (16%) to have unclear concern because we could not
determine concerns (Clemente 2017; Rose 2012; Togun 2016).
In the index test domain, we considered all studies at low risk of
bias because the results of the index tests were interpreted without
knowledge of the results of the reference standard and prespecified
thresholds were used, as relevant. Regarding applicability, with
respect to the index tests, we considered all studies to have low
concern.
In the reference standard domain, we considered three studies
(16%) to have low risk of bias because the results of the reference
standard were likely to correctly classify the target condition and
the results were interpreted without knowledge of the results of the
index test (PERCH 2019; Rose 2012; Ustero 2017). We considered
16 studies (84%) at unclear risk of bias because reference standard
results may have been influenced by results of the index test.
This was particularly a concern for studies assessing CXR against
a composite reference standard (Birungi 2018; Clemente 2017;
Dreesman 2017; Kruk 2008; LaCourse 2014; Schwoebel 2020;
Tieu 2014; Togun 2016; Triasih 2015b), and, to a lesser extent,
for studies assessing symptoms against a composite reference
standard (Aggerbeck 2018; Birungi 2018; Dreesman 2017; Jaganath
2013; Kruk 2008; LaCourse 2014; Portevin 2014; Rose 2012; Sawry
2018; Schwoebel 2020; Tieu 2014; Togun 2015; Togun 2016; Triasih
2015a; Vonasek 2021 – several studies evaluated more than one
index test). Regarding applicability, with respect to the reference
standards, we considered all studies to have low concern.
In the flow and timing domain, we considered 14 studies (74%) at
low risk of bias because there was an appropriate interval between
the index test and reference standard, all children received the
same reference standard, and all children were included in the
analysis. We considered three studies (16%) at high risk of bias:
for one study there was not an appropriate interval between the
index test and reference standard, not all children received the
same reference standard, and not all children were included in
the analysis (Sawry 2018); for one study it was unclear if there
was an appropriate interval between the index test and reference
standard and not all children received the same reference standard
(Ustero 2017); and for one study it was unclear if there was an
appropriate interval between the index test and reference standard
and not all children were included in the analysis (Vonasek 2021).
We considered two studies (10%) at unclear risk of bias: for one
study not all children received the same reference standard (PERCH
2019), and for one study it was unclear if there was an appropriate
interval between the index test and reference standard (Triasih
2015b).
Findings
Of the 19 studies, 17 (89%) were conducted mainly or exclusively
in low- or middle-income countries and two (11%) were conducted
exclusively in high-income countries (Clemente 2017; Dreesman
2017). Two studies only assessed participants living with HIV
(Sawry 2018; Vonasek 2021). Six studies did not report the HIV
status of participants. One study excluded participants living with
HIV (PERCH 2019). HIV prevalence in the remaining 10 studies
ranged from 0% (Togun 2015) to 37% (Rose 2012). Fourteen studies
were at least partially conducted in sub-Saharan African, four in
Asia (PERCH 2019; Tieu 2014; Triasih 2015a; Triasih 2015b), and
two in Europe (Clemente 2017; Dreesman 2017). Twelve studies
were conducted at least partially in tuberculosis high-burden
countries. FiQeen studies evaluated the accuracy of individual
symptoms for tuberculosis screening. Twelve studies evaluated
the accuracy of combinations of symptoms. Ten studies evaluated
CXR. Two studies evaluated Xpert MTB/RIF in a screening context
(LaCourse 2014; Togun 2015). Several studies assessed more than
one screening test. Six studies (32%) reported results against
a microbiological reference standard. Seventeen studies (89%)
reported results against a composite reference standard. Table 1
presents a summary of key characteristics of the included studies.
We presented details in the Characteristics of included studies
table. Table 2 presents summary values of sensitivity and specificity
for the following analyses.
1. Symptom screening for detection of pulmonary tuberculosis
One or more of cough, fever, or poor weight gain in close
tuberculosis contacts, against a composite reference standard
We identified four studies that used a composite reference standard
to estimate the accuracy of the symptom group cough, fever,
or poor weight gain to screen for pulmonary tuberculosis in
close tuberculosis contacts. Sensitivity estimates ranged from 64%
to 100%. The two studies with the lowest sensitivity (64% and
76%) only included children under five years of age (Kruk 2008;
Schwoebel 2020), possibly explaining diRerences in sensitivity
given the frequency with which 'asymptomatic hilar adenopathy'
may occur in this age group. Specificity estimates ranged from 40%
to 84%. Three studies had specificity of 69% or higher (Birungi
2018; Kruk 2008; Triasih 2015a). The single study with notably
lower specificity (40%) used a symptom screen that assessed the
presence of symptoms over the past month (Schwoebel 2020),
while the symptom screens of other studies were composed of
more focused symptoms present during a shorter time period. This
may explain diRerences in specificity. Pooled sensitivity was 89%
(95% CI 52% to 98%) and pooled specificity was 69% (95% CI 51%
to 83%) (4 studies, 2695 participants, 113 (4.2%) with tuberculosis)
(Figure 6).
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Figure 6.   Forest plots of symptom groups, the WHO four-symptom screen for people living with HIV, and nutrition
status to screen for pulmonary tuberculosis by composite reference standard. The squares represent the sensitivity
and specificity of one study, the black line its confidence interval. The individual studies are ordered by decreasing
sensitivity. BMI: body mass index; FN: false negative; FP: false positive; TN: true negative; TP: true positive.
 
One or more of cough, fever, or decreased playfulness in children
under five years of age in inpatient or outpatient settings,
against a composite reference standard
We identified three studies that used a composite reference
standard to estimate the accuracy of the symptom group
cough, fever, or decreased playfulness to screen for pulmonary
tuberculosis in children under five years of age in inpatient or
outpatient settings (Aggerbeck 2018; Kruk 2008; Schwoebel 2020).
Sensitivity estimates ranged from 64% to 76%. Specificity estimates
were 37% and 77% (3 studies, 2445 participants, 106 (4.3%) with
tuberculosis; Figure 6).
One or more of cough, fever, poor weight gain, or close
tuberculosis contact (WHO four-symptom screen) in children
living with HIV in outpatient settings, against a composite
reference standard
We identified two studies that used a composite reference standard
to estimate the accuracy of the WHO-recommended four-symptom
screen (current cough, fever, poor weight gain, or close tuberculosis
contact for children; current cough, weight loss, night sweats,
or fever for adolescents) to screen for pulmonary tuberculosis
in outpatients living with HIV at every clinical encounter (Sawry
2018; Vonasek 2021). Sensitivity estimates were 57% and 61%.
Specificity estimates were 89% and 97%. The WHO four-symptom
screen pooled sensitivity was 61% (95% CI 58% to 64%) and
pooled specificity was 94% (95% CI 86% to 98%) (2 studies;
20,926 participants, 1219 (5.8%) with tuberculosis; 203,135 screens)
(Figure 6).
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Undernutrition in close tuberculosis contacts, against a
composite reference standard
We identified three studies that used a composite reference
standard to estimate the accuracy of undernutrition (cutoR of body
mass index z-score or weight-for-age z-score of –2) to screen for
pulmonary tuberculosis in close tuberculosis contacts (Jaganath
2013; Tieu 2014; Togun 2015). Sensitivity estimates ranged from
10% to 35%. Specificity estimates ranged from 72% to 94%.
Undernutrition pooled sensitivity was 21% (95% CI 11% to 38%)
and pooled specificity was 85% (95% CI 71% to 93%) (3 studies,
1399 participants, 162 (11.6%) with tuberculosis (Figure 6).
Undernutrition in children in inpatient or outpatient settings,
against a composite reference standard
We identified five studies that used a composite reference standard
to estimate the accuracy of undernutrition (cutoR of body mass
index z-score or weight-for-age z-score of –2) to screen for
pulmonary tuberculosis in children in inpatient or outpatient
settings. Sensitivity estimates ranged from 10% to 55%. The two
studies with the highest sensitivities included inpatients likely
to have more severe disease (Portevin 2014; Rose 2012), while
the other three studies were exclusively conducted in outpatient
settings (Jaganath 2013; Tieu 2014; Togun 2015). This could
partially explain diRerences in sensitivity (range 10% to 55%).
Specificity estimates ranged from 47% to 94%. Undernutrition
pooled sensitivity was 32% (95% CI 18% to 50%) and pooled
specificity was 75% (95% CI 56% to 88%) (5 studies, 1723
participants, 233 (13.5%) with tuberculosis) (Figure 6).
Undernutrition in children in inpatient or outpatient settings,
against a microbiological reference standard
We identified two studies that used a microbiological reference
standard to estimate the accuracy of undernutrition (cutoR of
body mass index z-score or weight-for-age z-score of –2) to screen
for pulmonary tuberculosis in children in inpatient or outpatient
settings (Portevin 2014; Togun 2015). Sensitivity estimates were
48% and 67%. Specificity estimates were 62% and 72% (2 studies,
561 participants, 39 (7.0%) with tuberculosis) (Figure 6).
We identified no studies that evaluated symptom screening for
detection of pulmonary tuberculosis in children with pneumonia
and children in the general population in high-tuberculosis burden
settings.
2. Chest radiography for screening of pulmonary tuberculosis
Ten studies involving 7146 participants evaluated the accuracy of
CXR to screen for pulmonary tuberculosis and included 260 (3.5%)
participants with tuberculosis. The median number of participants
in the studies was 249 (interquartile range 158 to 300). Table
3 presents details of how CXR was obtained, how results were
interpreted, and threshold for positivity for these various studies.
Abnormal chest radiography in close tuberculosis contacts,
against a composite reference standard
We identified eight studies that used a composite reference
standard to estimate the accuracy of abnormal CXR to screen
for pulmonary tuberculosis in close tuberculosis contacts (Birungi
2018; Clemente 2017; Dreesman 2017; Kruk 2008; Schwoebel 2020;
Tieu 2014; Togun 2016; Triasih 2015b). Sensitivity estimates ranged
from 52% to 100%, with only one study (Triasih 2015b) having a
sensitivity below 78%. Specificity estimates ranged from 28% to
100%. In the meta-analysis, abnormal CXR pooled sensitivity was
87% (95% CI 75% to 93%) and pooled specificity was 99% (95%
CI 68% to 100%) (8 studies, 3513 participants, 232 (6.6%) with
tuberculosis) (Figure 7).
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Figure 7.   Forest plots of chest radiography (CXR) to screen for pulmonary tuberculosis. The squares represent the
sensitivity and specificity of one study, the black line its confidence interval. The individual studies are ordered by
decreasing sensitivity. FN: false negative; FP: false positive; TN: true negative; TP: true positive.
 
Figure 8 presents a summary plot of abnormal CXR sensitivity
and specificity to screen for pulmonary tuberculosis in close
tuberculosis contacts. The summary point (pooled value) appears
close to the upper leQ-hand corner of the plot, suggesting high
accuracy of this screening test. The 95% prediction region is
relatively wide, displaying uncertainty as to where the likely values
of sensitivity and specificity might occur in a future study.
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Figure 8.   Summary plot of abnormal chest radiography sensitivity and specificity to screen for pulmonary
tuberculosis in close tuberculosis contacts. Each individual study is represented by an empty oval. The size of the
oval is proportional to the sample size of the study such that larger studies are represented by larger ovals. The
dashed curves represent the 95% confidence region.
 
Suggestive chest radiography in close tuberculosis contacts,
against a composite reference standard
Four of the studies in the previous analysis used a composite
reference standard to estimate the accuracy of CXR findings more
specifically suggestive of tuberculosis (rather than an abnormal
CXR more generally) to screen for pulmonary tuberculosis in close
tuberculosis contacts. Sensitivity estimates ranged from 78% to
100%, though the estimate of 100% was from a study with only four
cases of tuberculosis (Birungi 2018). Three studies had specificity
estimates of 100%, though these studies together contributed less
than 30% of these data (Birungi 2018; Clemente 2017; Kruk 2008).
The largest study had a specificity estimate of 87% (Schwoebel
2020). For CXR suggestive of tuberculosis, pooled sensitivity was
84% (95% CI 70% to 92%) and pooled specificity was 91% (95%
CI 90% to 92%) (4 studies, 2550 participants, 113 (4.4%) with
tuberculosis) (Figure 7).
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Suggestive chest radiography in children under five years of
age in inpatient or outpatient settings, against a composite
reference standard
We identified three studies that used a composite reference
standard to estimate the accuracy of suggestive CXR findings to
screen for pulmonary tuberculosis in children under five years
of age in inpatient or outpatient settings (Kruk 2008; LaCourse
2014; Schwoebel 2020). Two of these studies were also included
in the previous analysis as they were conducted with populations
and in settings relevant to both analyses (Kruk 2008; Schwoebel
2020). Sensitivity estimates ranged from 78% to 100%. Specificity
estimates ranged from 87% to 100%. The largest of these studies,
contributing 77% of these data, notably had the lowest sensitivity
and specificity estimates (Schwoebel 2020). In the meta-analysis,
CXR suggestive of tuberculosis pooled sensitivity was 87% (95% CI
66% to 96%) and pooled specificity was 89% (95% CI 88% to 90%) (3
studies, 2388 participants, 110 (4.6%) with tuberculosis) (Figure 7).
Abnormal chest radiography in children under five years of age
with pneumonia in inpatient settings, against a microbiological
reference standard
We identified one study with participants from seven countries
(3540 children in total, 28 (0.8%) with tuberculosis) that used a
microbiological reference standard to estimate the accuracy of
abnormal CXR findings to screen for pulmonary tuberculosis in
children under five years of age hospitalized with pneumonia
(PERCH 2019). Sensitivity was 86% (95% CI 67% to 96%) and
specificity was 56% (95% CI 54% to 58%) (Figure 7).
We identified no studies that evaluated CXR for screening of
pulmonary tuberculosis in children living with HIV and children in
the general population in high-tuberculosis burden settings.
3. Xpert MTB/RIF for screening of pulmonary tuberculosis
Two studies involving 787 participants (300 from LaCourse 2014,
487 from Togun 2015) evaluated the accuracy of Xpert MTB/RIF to
screen for pulmonary tuberculosis.
Children in inpatient or outpatient settings, against a
microbiological reference standard
For the two studies, against a microbiological reference standard,
sensitivity estimates were 43% and 100%. Of note, these estimates
were derived from only two and 14 tuberculosis cases in each
study. Specificity estimates were 99% and 100%. These two
studies notably selected participants from diRerent populations,
with LaCourse 2014 enrolling children under five years of age
hospitalized with severe acute malnutrition and Togun 2015
enrolling tuberculosis household contacts under 15 years of age in
an outpatient setting (Figure 9).
 
Figure 9.   Forest plots of Xpert MTB/RIF sensitivity and specificity to screen for pulmonary tuberculosis by reference
standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval.
FN: false negative; FP: false positive; TN: true negative; TP: true positive.
 
Children in inpatient or outpatient settings, against a composite
reference standard
These two studies also used a composite reference standard to
estimate the accuracy of Xpert MTB/RIF to screen for pulmonary
tuberculosis in children in inpatient or outpatient settings
(LaCourse 2014; Togun 2015). Sensitivity estimates were 9% and
19%. Specificity estimates were both 100% (Figure 9).
We did not identify any studies that evaluated Xpert MTB/RIF for
screening of pulmonary tuberculosis in children living with HIV,
children with pneumonia, and children in the general population in
high tuberculosis burden settings.
D I S C U S S I O N
This systematic review summarized the current literature and
included 19 unique studies that estimated the accuracy of
symptoms, CXR, and Xpert MTB/RIF to screen for active pulmonary
tuberculosis in children.
Summary of main results
Symptom-based screening for pulmonary tuberculosis
• In close tuberculosis contacts, against a composite reference
standard, one or more of cough, fever, or poor weight gain
pooled sensitivity was 89% (95% CI 52% to 98%) and pooled
specificity was 69% (95% CI 51% to 83%) (4 studies, 2695
participants).
• In children under five years of age in inpatient or outpatient
settings, against a composite reference standard, one or more of
cough, fever, or decreased playfulness sensitivity range was 64%
to 76% and specificity range was 37% to 77% (3 studies, 2445
participants).
• In children living with HIV in outpatient settings, against a
composite reference standard, one or more of cough, fever, poor
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weight gain, or close tuberculosis contact (WHO four-symptom
screen), done at each healthcare visit, pooled sensitivity was
61% (95% CI 58% to 64%) and pooled specificity was 94% (95%
CI 86% to 98%) (2 studies; 20,926 participants).
• For any setting or population, against a composite reference
standard, undernutrition pooled sensitivity was 32% (95% CI
18% to 50%) and pooled specificity was 75% (95% CI 56% to
88%) (5 studies, 1723 participants).
• In close tuberculosis contacts, against a composite reference
standard, undernutrition pooled sensitivity was 21% (95% CI
11% to 38%) and pooled specificity was 85% (95% CI 71% to
93%) (3 studies, 1399 participants).
• In children in inpatient or outpatient settings, against a
microbiological reference standard, undernutrition sensitivities
were 48% and 67% and specificities were 62% and 72% (2
studies, 561 participants).
Chest radiography screening for pulmonary tuberculosis
• In close tuberculosis contacts, against a composite reference
standard, abnormal CXR pooled sensitivity was 87% (95% CI 75%
to 93%) and pooled specificity was 99% (95% CI 68% to 100%) (8
studies, 3513 participants).
• In close tuberculosis contacts, against a composite reference
standard, CXR suggestive of tuberculosis pooled sensitivity was
84% (95% CI 70% to 92%) and pooled specificity was 91% (95%
CI 90% to 92%) (4 studies, 2550 participants).
• In children under five years of age in inpatient or outpatient
settings, against a composite reference standard, CXR
suggestive of tuberculosis pooled sensitivity was 87% (95% CI
66% to 96%) and pooled specificity was 89% (95% CI 88% to
90%) (3 studies, 2388 participants).
• In children under five years of age hospitalized with pneumonia,
against a microbiological reference standard, abnormal CXR
sensitivity was 86% (95% CI 67% to 96%) and specificity was 56%
(95% CI 54% to 58%) (1 study, 3540 participants).
Xpert MTB/RIF screening for pulmonary tuberculosis
• In children in inpatient or outpatient settings, against a
microbiological reference standard, Xpert MTB/RIF sensitivities
were 43% and 100% and specificities were 99% and 100% (2
studies, 787 participants).
• In children in inpatient or outpatient settings, against a
composite reference standard, Xpert MTB/RIF sensitivities were
9% and 19% and specificities were both 100% (2 studies, 787
participants).
Illustration of findings in a hypothetical population of 1000
children with 5% prevalence of tuberculosis
One or more of cough, fever, or poor weight gain for screening of
pulmonary tuberculosis in tuberculosis close contacts
If 50 of the 1000 children have pulmonary tuberculosis by a
composite reference standard, 339 would have cough, fever, or poor
weight gain, 294 (87%) of whom would not have tuberculosis (false
positives); 661 would not have cough, fever, or poor weight gain, 5
(1%) of whom would have tuberculosis (false negatives) (Summary
of findings 1).
One or more of cough, fever, or decreased playfulness for
screening of pulmonary tuberculosis in children under five years
of age in inpatient or outpatient settings
If 50 of the 1000 children have pulmonary tuberculosis by a
composite reference standard, 251 to 636 would have cough, fever,
or decreased playfulness, 219 to 598 (87% to 94%) of whom would
not have tuberculosis (false positives); 364 to 749 would not have
cough, fever, or decreased playfulness, 12 to 18 (2% to 3%) of whom
would have tuberculosis (false negatives) (Summary of findings 1).
One or more of cough, fever, poor weight gain, or tuberculosis
close contact (WHO four-symptom screen) for pulmonary
tuberculosis in outpatients living with HIV at every healthcare
visit
If 50 of 1000 WHO four-symptom screens are on children with
pulmonary tuberculosis by a composite reference standard, 88
symptom screens would be positive, 57 (65%) of which would be
on children who do not have tuberculosis (false positives); 912
symptom screens would be negative, 19 (2%) of which would be
on children who have tuberculosis (false negatives) (Summary of
findings 1).
Abnormal chest radiography for screening of pulmonary
tuberculosis in tuberculosis close contacts
If 50 of the 1000 children have pulmonary tuberculosis by a
composite reference standard, 63 would have abnormal CXR, 19
(30%) of whom would not have tuberculosis (false positives);
937 would not have abnormal CXR, 6 (1%) of whom would have
tuberculosis (false negatives) (Summary of findings 2).
Xpert MTB/RIF for screening of pulmonary tuberculosis in
children in inpatient or outpatient settings
If 50 of the 1000 children have pulmonary tuberculosis by a
microbiological reference standard, 31 to 69 would be Xpert
MTB/RIF-positive, 9 to 19 (28 to 29%) of whom would not have
tuberculosis (false positives); 969 to 931 would be Xpert MTB/RIF-
negative, 0 to 28 (0 to 3%) of whom would have tuberculosis (false
negatives) (Summary of findings 3).
Symptom-based screening for pulmonary tuberculosis
Symptom-based screening for tuberculosis has the obvious
advantages of not requiring any materials other than a careful
interviewer and providing instant results. However, symptoms of
childhood tuberculosis, particularly in young children, tend to
overlap with symptoms of common childhood conditions and to
be non-specific, especially if poorly defined (Marais 2005a; Marais
2005b). Therefore, symptom-based screening is most likely to be
beneficial when targeted to high-risk groups.
We reported a meta-analysis of the symptom group 'cough, fever,
or poor weight gain' in close tuberculosis contacts. While pooled
sensitivity was 89% (95% CI 52% to 98%), specificity was lower
(69%, 95% CI 51% to 83%) with this approach tending to have
more false-positive screens due to multiple symptoms lowering
the threshold for positive screening. Composed symptom screens
such as 'cough, fever, or poor weight gain' may lack specificity, but
this may be tolerable in contexts where the consequences of false-
positive screening are less of a concern. For example, in settings
where resources are less constrained and the costs of unnecessary
diagnostic work-up are relatively tolerable. DiRerent combinations
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of symptoms for composed symptom screens may oRer better
accuracy for high-risk groups; this is an area in need of research.
For people living with HIV or children in close contact with
a tuberculosis case, tuberculosis preventive treatment is highly
eRective at reducing the risk of developing tuberculosis disease.
Tuberculosis preventive treatment is recommended for children
in these high-risk groups aQer tuberculosis disease has been
excluded. Screening strategies can dictate who is eligible for
preventive treatment. Those screening negative for tuberculosis
disease can be considered for preventive treatment, while those
screening positive must complete additional diagnostic work-up
for tuberculosis disease while preventive treatment is withheld
(WHO Consolidated Guidelines (Module 1) 2020). These screening
strategies must maximize sensitivity so that false-negative results,
with consequent provision of tuberculosis preventive treatment
to someone who has tuberculosis disease is prevented. Having a
rapid and easy-to-perform screening test should assist preventive
treatment reaching more children who could potentially benefit.
Another consideration relevant to screening children eligible for
tuberculosis preventive treatment is the severity of tuberculosis
disease. Young children with tuberculosis tend to have
paucibacillary disease, (oQen manifesting as asymptomatic hilar
adenopathy), which would result in a false-negative screen in this
review given the positive CXR. However, concerns regarding risk
of transmission and creating drug resistance with one- or two-
drug preventive treatment regimens are minimal for those with
asymptomatic disease who initiate preventive treatment in this
age group (Marais 2009a). Therefore, lower sensitivity may be
tolerable if those with false-negative screens mostly have mild,
paucibacillary disease and start preventive treatment while those
with severe disease are appropriately captured by the screen. Some
consideration also needs to be made for screening specificity when
it dictates eligibility for preventive treatment. Lower specificity
screens would result in more missed or delayed opportunities
to initiate preventive treatment due to false-positive screening.
Hence, although the symptom group cough, fever, or poor weight
gain in close tuberculosis contacts had high sensitivity at 89%, the
limited specificity at 69% is an important consideration.
It should be noted that we evaluated these symptom groups in
studies that also considered additional symptoms within study-
specific symptom screening strategies. Therefore, these additional
symptoms may have captured cases of tuberculosis disease when
the three symptoms from the group evaluated were not present;
in turn, this would lead to enumeration of a true-positive result
and possibly inflating sensitivity estimates. Conversely, study-
specific symptom screening strategies may have utilized diRerent
duration of symptoms for positivity (e.g. 'current cough' versus
'cough greater than two weeks'), and these diRering screening
definitions may limit applicability of the findings to other settings.
Hence, we advise interpreting the symptom group results with
caution and emphasize that the 'cough, fever, or poor weight
gain' symptom group screen in close tuberculosis contacts requires
further investigation as a potentially high sensitivity screening
strategy.
We assessed the WHO-recommended symptom screen for people
living with HIV (where it is essentially a three-symptom screen
accompanied by a question on recent tuberculosis exposure)
in children and adolescents presenting to outpatient settings.
Against a composite reference standard, as described above, the
specificity of 94% is important for this population eligible for
tuberculosis preventive treatment. The limited sensitivity (61%) is
a concern given that children living with HIV tend to have more
rapidly progressive tuberculosis disease (similar to very young
children) and tuberculosis preventive treatment could potentially
be given to someone with tuberculosis disease. However, synthesis
of these data should be considered within the context of this
screening strategy that is recommended to be performed serially
at every clinical encounter. Therefore, the deleterious eRects
of an inaccurate screen at a single clinical encounter may be
minimized by accurate screening results of the same child in the
near future. This highlights the importance of ongoing screening
for tuberculosis disease while preventive treatment is being
administered.
Chest radiography screening for pulmonary tuberculosis
In the absence of a microbiological diagnosis, the diagnosis
of pulmonary childhood tuberculosis is heavily influenced by
chest imaging, when locally available. This reliance on chest
imaging remains the reality in the clinical setting, despite evidence
showing limited accuracy of CXR for detecting lesions suggestive
of childhood tuberculosis, such as mediastinal lymphadenopathy,
compared to computed tomography (Swingler 2005), and poor
inter-reader agreement for CXR findings suggestive of tuberculosis
(Du Toit 2002; Kaguthi 2014; Swingler 2005). Of the 10 studies
assessing CXR, only one study reported inter-reader agreement
(Triasih 2015b). Six studies required agreement between at least
two interpreters to define positive CXR (Birungi 2018; Kruk 2008;
LaCourse 2014; PERCH 2019; Togun 2016; Triasih 2015b), and of
the five studies that reported level of training of interpreters, all
were trained physicians at minimum (Birungi 2018; PERCH 2019;
Schwoebel 2020; Togun 2016; Triasih 2015b). Characteristics of how
CXR was obtained and interpreted were not reported in enough
included studies to allow for analysis of how these factors influence
test accuracy.
Although our data suggest that a lower threshold for positivity ('any
abnormality' rather than 'abnormality suggestive of tuberculosis')
may give more accurate screening results when applied to
close tuberculosis contacts, we noted that these estimates
were imprecise (with greatly overlapping 95% CIs) and direct
comparisons of the accuracy of these two thresholds were
invalid given that they were reported from diRerent studies.
Also, study-specific threshold for positivity varied between
studies categorized as having thresholds of 'any abnormality'
or 'abnormality suggestive of tuberculosis,' and this further
complicated comparisons between these thresholds.
Against a composite reference standard, we found that CXR with
'any abnormality' in close tuberculosis contacts had a sensitivity
of 87% and a specificity of 99%. We found similarly high accuracy
for CXR suggestive of tuberculosis against a composite reference
standard in children under five years of age in inpatient or
outpatient settings. One systematic review of CXR with any
abnormality in the general population of adults, against a
microbiological reference standard, reported pooled estimates of
sensitivity from three studies of 98% (95% CI 95% to 100%) and
specificity of 75% (95% CI 72% to 79%) (van't Hoog 2013). Since
it is theorized that comparison against a microbiological reference
standard overestimates sensitivity and underestimates specificity
of the index test (Drain 2019), we considered estimates of CXR
in children against a composite reference standard to be fairly
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consistent with these estimates for adults. Indeed, we reported
one large, multi-country study with data for abnormal CXR in
children under the age of five years against a microbiological
reference standard; of note, sensitivity was similarly high at 86%
while specificity was much lower at 56% (PERCH 2019). PERCH
2019 evaluated children with severe pneumonia, a population
very likely to have CXR abnormalities due to pathology other
than tuberculosis, and this also explains the low specificity in
this study. As detailed above, in situations where screening would
dictate who should be considered for tuberculosis preventive
treatment, high sensitivity is the key criterion to guide preventive
treatment while low specificity, to a degree, can be tolerable if
supplemented by additional testing. Nevertheless, we interpreted
the accuracy estimates reported here for CXR against a composite
reference standard with caution given the concerns of bias and
imprecision (see Strengths and weaknesses of the review, Accuracy
of the reference standards used). These findings of high accuracy
for the high-risk group of close tuberculosis contacts suggest
that this is a promising screening strategy requiring further
investigation. We identified limited CXR data for high-risk groups
such as malnourished children and the general population in high
tuberculosis burden settings.
Xpert MTB/RIF screening for pulmonary tuberculosis
We found that Xpert MTB/RIF had screening sensitivity of 43% and
100% and specificity of 99% and 100%. Although the sensitivity
estimates are based on very few tuberculosis cases, these findings
are similar to reported accuracy estimates for Xpert MTB/RIF in
paediatric diagnostic studies. Diagnostic studies apply this test
to children with presumptive tuberculosis, a context in which the
accuracy of Xpert MTB/RIF has been much more robustly evaluated
as opposed to a screening context as in this review. One Cochrane
Review of the diagnostic accuracy of Xpert MTB/RIF for childhood
tuberculosis against a microbiological reference standard reported
sensitivities ranging from 45.7% to 73.0% for various specimen
types and specificity of over 98% for all specimen types considered
(Kay 2020). Given the high specificity but likely limited sensitivity of
this assay, Xpert MTB/RIF may have an important role as an early
'rule-in' strategy for tuberculosis case finding in high-risk groups.
Although the evidence suggests that Xpert MTB/RIF should not be
implemented as a stand-alone screening strategy, the strengths of
this test (high specificity and relatively fast results in contexts with
adequate resources) may be leveraged with it as one component
of a larger screening approach. As resources allow, Xpert MTB/RIF
could be used broadly to screen high-risk groups of children so
that those with positive results are quickly started on treatment
and those with negative results are more carefully evaluated with
more sensitive strategies. However, in many high tuberculosis-
burden settings, resource limitations require more judicious use
of Xpert MTB/RIF testing so it is more appropriately used later
in case finding algorithms, aQer less resource-intensive strategies,
such as symptom screening, have been employed. We did not
assess combination screening strategies in this review, but high-
quality studies evaluating diRerent combinations and sequences
of screening tests for high-risk populations are urgently needed to
improve childhood tuberculosis case finding.
Strengths and weaknesses of the review
Completeness of evidence
We performed comprehensive searches of numerous databases,
handsearching references of included studies, and contacting
experts in the field of paediatric tuberculosis for additional
evidence. Non-English studies were included in the search and
assessed for inclusion in this review. Despite the exhaustive
approach, we acknowledge that some relevant studies may have
been missed. There was a relatively high number of missing full
texts (65 of 610 full-text studies sought; 11%) of studies that were,
therefore, not fully assessed for inclusion. This was mostly an issue
for older studies as 71% of those with missing full texts were
published before 1980. Given that knowledge and techniques for
diagnosis of tuberculosis in children has changed substantially over
the past few decades, this issue of missing pre-1980 full texts is less
of a concern.
Accuracy of the reference standards used
We used two reference standards in this review, microbiological
and composite. We do not consider either of these to be superior,
as each has its respective limitations for detecting pulmonary
tuberculosis in children. Due to the paucibacillary nature of
childhood tuberculosis, the lower detection limit of existing
microbiological reference standards may be too high to capture
a significant proportion of cases; thus, comparison against a
microbiological reference standard may potentially overestimate
the sensitivity and underestimate the specificity of the index test
(Drain 2019). Another consideration for comparisons against the
microbiological reference standard is variation between number
of specimens tested for a particular individual, with multiple
specimen testing likely increasing the yield of the reference
standard (Cruz 2012; Zar 2012), and thereby influencing accuracy
estimates of the index test. Accuracy of microbiological testing
for pulmonary childhood tuberculosis also varies by the type of
specimen collected, with invasively collected specimens, such as
gastric aspirates, typically more accurate in younger children (Dunn
2016; Kay 2020). Given the limited data available for this review
against a microbiological reference standard, we did not investigate
the number of specimens tested or type of specimen.
The composite reference standard may overdiagnose tuberculosis;
in turn, this may underestimate sensitivity and overestimate
specificity of the index test (Drain 2019). We defined the composite
reference standard as microbiological confirmation or author-
defined clinical pulmonary tuberculosis, with a requirement that
any clinical diagnosis have a follow-up visit to help verify the
diagnosis. Hence, clinical characteristics and component tests
in the composite reference standard diRered across studies;
these diRerences may have contributed to variation in accuracy
estimates. Incorporation bias was a particular concern when
symptoms or CXR were the index tests compared against the
composite reference standard. Symptoms and CXR are inherent
components of a clinical diagnosis of tuberculosis; if agreement
between the index test and the reference standard increases,
accuracy will be overestimated due to incorporation bias. Although
there is limited evidence that incorporation bias significantly
alters accuracy estimates in diagnostic accuracy studies (Rutjes
2006; Whiting 2013), this is potentially a much larger problem in
paediatric research where an independent reference standard is
much more diRicult to achieve.
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Methodological and reporting quality of the included studies
Using QUADAS-2, we considered risk of bias to be low for the
patient selection and index test domains. Risk of bias was unclear
for the reference standard domain largely due to concerns for
incorporation bias with the composite reference standard, but with
respect to the microbiological reference standard, risk of bias was
low. Risk of bias for the flow and timing domain was low for 14 (74%)
studies but high for six studies because of unclear timing between
the index test and reference standard. The included studies were
generally well reported. For a few of the studies where extraction
of the data was not clear, we corresponded with the primary study
authors to ensure appropriate data extraction. Overall, the studies
had low risk of bias and were well reported.
Comparison with other systematic reviews
We are not aware of other systematic reviews assessing the
accuracy of symptom screening, CXR, or Xpert MTB/RIF for
screening of childhood tuberculosis. One systematic review
of symptom screening and CXR for tuberculosis in adults
was discussed above (see 'Chest radiography screening for
pulmonary tuberculosis;' van't Hoog 2013). A Cochrane Review
of Xpert MTB/RIF and Xpert Ultra for pulmonary tuberculosis
in adults irrespective of signs or symptoms of pulmonary
tuberculosis is similar to our assessment of Xpert MTB/RIF as a
screening strategy (Shapiro 2021). However, especially for younger
children, comparisons between paediatric and adult pulmonary
tuberculosis are challenging because the diseases are so diRerent.
One Cochrane Review of Xpert MTB/RIF diagnostic accuracy for
childhood tuberculosis reported accuracy estimates that were
similar to the estimates in this review for Xpert MTB/RIF used in
a screening context (Kay 2020). However, our findings for Xpert
MTB/RIF accuracy were limited as the numbers of studies and
participants enrolled were small.
Applicability of findings to the review question
To assess the applicability of findings to the review question,
we considered QUADAS-2 domains for patient selection, index
test, and reference standard. With respect to the patient selection
domain, we considered most studies to have low concern
about applicability. A few smaller studies had unclear or high
concern about applicability in the patient selection domain due
to enrolment criteria which implied a diagnostic, rather than
screening, application. It should be acknowledged that there is
a spectrum between screening and diagnosis rather than a clear
distinction. Many studies were excluded from this review because
there was consensus among the review authors that they were
diagnostic studies. All included studies were determined by the
review authors to have applied the index tests in a 'screening
context,' as defined in the Background under 'Screening,' although
many studies included here may not be considered 'screening'
under stricter definitions of the term. With respect to the index test
and reference standard domains, all studies had low concern about
applicability.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found that in children who are tuberculosis contacts or living
with HIV, screening tests using symptoms or chest radiography
may be useful; however, both sensitivity and specificity estimates
are likely to be overestimated owing to incorporation bias. In
close tuberculosis contacts, the symptom screen including one
or more of cough, fever, or poor weight gain misses around 10%
of children who have tuberculosis at the initial screen; however,
these asymptomatic 'cases' are likely to have paucibacillary disease
for which tuberculosis preventive treatment may be curative and
the risk of inducing drug resistance is minimal. Single use of the
World Health Organization (WHO)-recommended 'four-symptom'
screen in children living with HIV had limited sensitivity, which is
concerning given their risk of rapid disease progression. Repeated
use of symptom screening at regular clinical encounters should
improve 'cumulative sensitivity' among children living with HIV,
but this was not assessed in this review. Chest radiography
(any abnormality) seems to be the most accurate screening
test for pulmonary tuberculosis in children but is influenced
by radiograph quality and inter-reader variability, as well as
potential overestimation of both sensitivity and specificity given
inclusion bias. Xpert MTB/RIF demonstrates high specificity, though
evaluation of sensitivity is limited by few studies and few children
with tuberculosis.
Implications for research
Research to identify accurate and practical screening tests for
pulmonary tuberculosis in children remains an urgent need. A
major limitation of most studies to date has been the absence
of a consistent and objective reference standard. Further, studies
assessing the accuracy of screening tests should use both
microbiological and composite reference standards and avoid
incorporation bias. Although these reference standards have
limitations, their combined use provides added value. In addition,
to foster robust accuracy estimates, study participants should be
tested with a reference standard for tuberculosis regardless of their
screening test result being positive or negative. Comparison of
studies that assess diRerent screening tests and strategies in the
same population should be conducted.
Studies assessing symptom screening tests need to consider the
intended use of the test with prioritization of high sensitivity,
particularly in high-risk groups. In close tuberculosis contacts,
additional studies assessing the utility of simple symptom
screening strategies are needed; these studies must use clear and
consistent symptom definitions. For the WHO-recommended 'four-
symptom' screen for children living with HIV, future studies should
assess the added value of serial screening, ideally completed once
every one to three months as part of routine clinical care. As
accuracy may diRer, more data are also needed in children living
with HIV who are naive to antiretroviral therapy or those with
advanced HIV.
Studies assessing chest radiography screening should consider
microbiological testing of multiple and diRerent specimens and
clinical follow-up to strengthen the definition of a reference
standard without concerns about incorporation bias. Given the
promising results for chest radiography screening in tuberculosis
close contacts, evaluation of this screening test in other high-risk
groups (e.g. malnourished children, children living with HIV) should
be a priority.
Xpert MTB/RIF and newer rapid molecular diagnostics (e.g. Xpert
Ultra) that have lower limits of bacilli detection are potentially
powerful screening tools for high-risk groups. Large, prospective,
well-designed studies are needed to assess their screening
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accuracy in children living with HIV; close tuberculosis contacts;
or children with malnutrition, unremitting cough, and pneumonia.
These studies should additionally compare the accuracy of various
sampling techniques, such as stool or oral swabs, given the need for
optimal feasibility and acceptability. Finally, studies should ideally
assess fresh specimens obtained within routine clinical settings.
Assessment of feasibility and cost eRectiveness are important to
inform implementation strategies, especially in resource-limited
settings where chest radiography or rapid molecular tests may not
be readily available. Improved screening is paramount if we are to
increase tuberculosis preventive treatment in children in high-risk
groups without disease and decrease treatment delays in children
with disease. New strategies should ideally be rapid, inexpensive,
feasible, and acceptable to children and their caregivers.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: children with signs of TB, symptoms of TB, or
close contact to a sputum smear TB-positive case
Age: < 5 years
Sex: 51% female overall (not reported for the < 5-year subgroup)
HIV infection: 25% overall (not reported for the < 5-year subgroup)
Sample size included for analysis: 235
Setting: outpatient
Country: South Africa
World Bank Income Classification: upper middle
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: composite reference standard
8.1%, microbiological reference standard 1.4%
Index tests Children with 1 of following symptoms concerning for TB: fever,
cough, decreased playfulness, or night sweats
Target condition and reference standard(s) Active TB not specified as pulmonary
Microbiological reference standard and composite reference stan-
dard (includes those diagnosed by clinical symptoms)
Flow and timing Timing between index test and reference standard not reported.
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Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    




Screening tests for active pulmonary tuberculosis in children (Review)










Cochrane Database of Systematic Reviews
Study characteristics
Patient Sampling Prospective, cross-sectional, consecutive
Patient characteristics and setting Enrolment criteria: child contacts of sputum smear TB-positive
cases
Age: < 15 years, median 6 years (IQR 2–13 years)
Sex: 49% female
HIV infection: 6%
Sample size included for analysis: 216
Setting: outpatient
Country: Rwanda
World Bank Income Classification: low
High TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 1.9%
Index tests TB contact; CXR; 1 of multiple symptoms – cough > 1 week,
haemoptysis, fever, failure to gain weight, absence of appetite, fa-
tigue, or presence of lymphadenopathy
Target condition and reference standard(s) Pulmonary TB
Composite reference standard: defined as microbiologically con-
firmed or unconfirmed TB (symptoms suggestive of TB and CXR
consistent with active TB)
Flow and timing Timing between index test and reference standard not reported.







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Birungi 2018 
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Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Retrospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: children referred mostly for TB contact and
less commonly for concerning symptoms
Age: < 15 years, mean 5.8 years (SD 3.9 years)
Sex: 50% female
HIV infection: not reported
Clemente 2017 
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Sample size included for analysis: 246
Setting: outpatient
Country: Italy
World Bank Income Classification: high
High TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 8.9%
Index tests CXR
Target condition and reference standard(s) Active TB not specified as pulmonary
Composite reference standard: based upon symptoms, CXR, TST,
and microbiological testing
Flow and timing Timing between index test and reference standard not reported.







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Clemente 2017  (Continued)
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Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: children recently exposed to a sputum smear
TB-positive adult
Age: < 15 years, mean 4.25 years (range 0–14 years)
Sex: 44% female
HIV infection: not reported
Sample size included for analysis: 61
Setting: inpatient
Country: Belgium
World Bank Income Classification: high
High TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 24.6%
Index tests TB contact, CXR
Dreesman 2017 
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Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: specific criteria not defined but in-
volved assessment of signs and symptoms, TST, CXR, and microbi-
ological testing
Flow and timing Timing between index test and reference standard not reported.







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Dreesman 2017  (Continued)
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Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, unclear sampling strategy
Patient characteristics and setting Enrolment criteria: child household contacts of adults with con-
firmed TB, with ≥ 1 week of contact in the last 3 months
Age: < 15 years, median 6 years (IQR 0–12 years)
Sex: 47% female
HIV infection: 3%
Sample size included for analysis: 761
Setting: outpatient
Country: Uganda
World Bank Income Classification: low
High TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 10.4%
Index tests TB contact, weight for BMI for age z-score < –2
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: defined as culture confirmation or
positive response to TB therapy with ≥ 2 of fever, cough > 2 weeks,
weight loss, positive TST, CXR consistent with active TB, or failure
to respond to empiric antibiotics over 2 weeks.
Flow and timing Timing between Index test and reference standard not reported.
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Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Jaganath 2013  (Continued)
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Patient Sampling Prospective, cohort, purposive
Patient characteristics and setting Enrolment criteria: child household contacts of adults with con-
firmed TB
Age: < 5 years, median 30 months (range 1–60 months)
Sex: 44% female
HIV infection: not reported
Sample size included for analysis: 252
Setting: outpatient
Country: South Africa
World Bank Income Classification: upper middle
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: microbiological reference
standard 0.7%, composite reference standard 13.1%
Index tests TB contact, cough, fever, weight loss, fatigue or lethargy, CXR
≥ 1 of cough, fever, weight loss, or fatigue
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: defined as decision to treat.
Flow and timing Index test and reference standard reported as occurring on the
same day.







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Kruk 2008 
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Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cross-sectional, consecutive
Patient characteristics and setting Enrolment criteria: severe acute malnutrition
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Sample size included for analysis: 300
Setting: inpatient
Country: Malawi
World Bank Income Classification: low
High TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: microbiological reference
standard 0.7%, composite reference standard 7.3%
Index tests TB contact, cough > 1 week, fever > 1 week, fatigue or lethargy,
MUAC < 11.5 cm, weight for height z-score < –3, CXR, Xpert MTB/
RIF
Target condition and reference standard(s) Active TB not specified as pulmonary.
Microbiological reference standard
Composite reference standard: defined as confirmed or probable
TB.
Flow and timing Index test and reference standard reported as occurring during a
single hospital admission.
Minimal missing data for most index tests except for weight for
height z-scores, which were only reported for those without oede-






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
LaCourse 2014  (Continued)
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, case-control with respect to pneumonia (only cases
analyzed for this review), consecutive
Patient characteristics and setting Enrolment criteria: WHO-defined severe or very severe pneumonia
Age: 41% 28 days to 5 months, 23% 6–11 months, 23% 12–23
months, 14% 24–59 months
Sex: 42% female
HIV infection: 0%
Sample size included for analysis: 3540
Setting: inpatient
Country: Bangladesh, The Gambia, Kenya, Mali, South Africa, Thai-
land, and Zambia
PERCH 2019 
Screening tests for active pulmonary tuberculosis in children (Review)










Cochrane Database of Systematic Reviews
World Bank Income Classification: 'low' for The Gambia and Mali;
'low-middle' for Bangladesh, Kenya, and Zambia; 'upper-middle'
for South Africa and Thailand
High TB burden country: Bangladesh, Kenya, South Africa, Thai-
land, and Zambia
High TB/HIV burden country: Kenya, South Africa, Thailand, and
Zambia
Prevalence of TB cases in the study: 0.8%
Index tests CXR
Target condition and reference standard(s) Active TB not specified as pulmonary.
Microbiological reference standard: culture (unspecified type)
positive
Flow and timing Index test conducted and reference standard collected both upon
enrolment
All reported participants had index and reference standards.
11% did not have microbiological reference standard, but they
were not included in the analysis (2×2 table).
Comparative  
Notes 11% did not have microbiological reference standard, but they




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
PERCH 2019  (Continued)
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Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: ≥ 1 of cough > 14 days, repeated fever, weight
loss or poor weight gain; and signs and symptoms that suggested
extrapulmonary TB
Age: < 15 years; median 6.1 years (IQR 2.1–10.3 years)
Sex: 46% female
HIV infection: 29%
Sample size included for analysis: 113
Setting: outpatient and inpatient
Country: Tanzania
World Bank Income Classification: low
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: microbiological 15.9%, com-
posite 33.6%
Portevin 2014 
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Index tests Cough, fever, fatigue or lethargy, weight loss, weight or BMI for age
z-score < –2
Target condition and reference standard(s) Active TB not specified as pulmonary.
Microbiological reference standard: MGIT liquid culture or LJ solid
culture positive
Composite: microbiological diagnosis, highly probable TB, or
probable TB
Flow and timing Timing between index tests and reference standard not reported;
all participants had reported index and reference standards.
Comparative  
Notes Strict selection criteria raised concern that included participants




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    High
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Portevin 2014  (Continued)
Screening tests for active pulmonary tuberculosis in children (Review)










Cochrane Database of Systematic Reviews
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: ≥ 1 of the following symptoms – fever, cough, weight
loss, or poor weight gain over ≥ 2 weeks; exposure to TB case in the last
2 years; seeking health care multiple times over the last 3 months; or
weight-for-age z-score < –2
Age: < 15 years; mean 4.4 years (SD 3.8 years)
Sex: 41% female
HIV infection: 37%
Sample size included for analysis: 211
Setting: outpatient and inpatient
Country: Tanzania
World Bank Income Classification: low
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 15.6%
Index tests Weight-for-age z-score < -2; ≥ 1 of fever, cough, weight loss, or poor weight
gain over ≥ 2 weeks; exposure to TB case in the last 2 years; seeking health
care multiple times over the last 3 months, or weight-for-age z-score < –2
(only positives)
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: microbiological diagnosis (LJ solid culture
positive) or highly probable TB
Rose 2012 
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Flow and timing Timing between index tests and reference standard not reported; all par-
ticipants had reported index and reference standards.
Comparative  
Notes Strict selection criteria raised concern that included participants did not
match the review question.
The composite reference standard was stricter and was relatively objec-
tive, and the main index test here (weight-for-age z-score) did not obvious-
ly influence the reference standard. In this way, although it is not clearly
stated that the reference standard was determined blinded to the index
tests, this reference standard was less susceptible to incorporation bias.
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced
bias?
  Low risk  
Are there concerns that the included patients and
setting do not match the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct,
or interpretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Unclear    
Could the reference standard, its conduct, or its in-
terpretation have introduced bias?
  Low risk  
Rose 2012  (Continued)
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Are there concerns that the target condition as de-
fined by the reference standard does not match the
question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: HIV positive, initiating antiretroviral therapy
Age: < 9 years; median 2.1 years (IQR 0.8–4.7 years)
Sex: 47% female
HIV infection: 100%
Sample size included for analysis: 1346 screens on 220 children
Setting: outpatient
Country: South Africa
World Bank Income Classification: upper-middle
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 3.2%
Index tests Intensified case finding symptom screen: any 1 of current cough or
fever, poor weight gain, or contact with a person with TB
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: microbiological diagnosis, proba-
ble TB, or possible TB
Flow and timing Timing between index tests and reference standard not reported.
Among the 220 children serially screened, receipt of the reference
standard was inconsistent because 20 opted out of the study, 17
were lost to follow-up, 13 transferred out, and 2 died.
Comparative  
Sawry 2018 
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Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
No    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? No    
Could the patient flow have introduced bias?   High risk  
Sawry 2018  (Continued)
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Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: household contact with adult smear-positive
TB case, plus either any symptom, clinical sign, or radiographic
finding suggestive of TB
Age: < 5 years; mean 2.6 years
Sex: 50% female
HIV infection: 1.8%
Sample size included for analysis: 1958
Setting: outpatient
Country: Benin, Burkina Faso, Cameroon, and Central African Re-
public
World Bank Income Classification: Cameroon is 'low-middle', the
other 3 are 'low'
High TB burden country: only Central African Republic
High TB/HIV burden country: only Central African Republic
Prevalence of TB cases in the study: 2.3%
Index tests Any 1 of the following within the past 4 weeks: cough, fever,
weight loss, reduced appetite, or reduced playfulness; weight-for-
height z-score < –3; CXR
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: microbiological diagnosis, proba-
ble TB (based on both clinical and radiological abnormalities, or
possible TB (based on signs and symptoms only)
Flow and timing Timing between index tests and reference standard not reported;
minor missing data for index tests (highest at 6.5% for CXR).
Comparative  
Notes TB close contacts without signs, symptoms, or radiographic find-
ings not suggestive of TB notably did not receive microbiological




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
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Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: close contact with adult TB cases within past
year
Tieu 2014 
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Age: < 15 years; mean 7.2 years (SD 4.2 years)
Sex: 48% female
HIV infection: 1.9%
Sample size included for analysis: 158
Setting: outpatient
Country: Thailand
World Bank Income Classification: upper-middle
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: microbiological 4.4%, com-
posite 13.3%
Index tests TB contact (only positives); current fever; weight-for-age or BMI-
for-age z-score < –2; weight loss or poor weight gain; CXR
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: definite, probable, and possible
TB
Flow and timing Index test and reference standard reported as occurring on the







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
Tieu 2014  (Continued)
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cross-sectional, consecutive
Patient characteristics and setting Enrolment criteria: household contact of adult smear-positive TB
cases
Age: < 15 years; median 6 years (IQR 3–9 years)
Sex: 47% female
HIV infection: 0%
Sample size included for analysis: 487
Setting: outpatient
Country: The Gambia
World Bank Income Classification: low
High TB burden country: no
Togun 2015 
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High TB/HIV burden country: no
Prevalence of TB cases in the study: microbiological 4.4%, com-
posite 12.9%
Index tests Cough or fever > 1 week, or both; BMI-for-age z-score < –2; CXR;
Xpert MTB/RIF
Target condition and reference standard(s) Active TB not specified as pulmonary.
Microbiological: both MGIT liquid culture system and LJ solid cul-
ture
Composite reference standard: microbiological diagnosis or clin-
ical diagnosis, defined as: suggestive appearance on chest radi-
ograph; and either favourable response to specific anti-TB thera-
py, positive TST, or suggestive histological appearances on biopsy
material.
Flow and timing Index test and reference standard reported as occurring on the







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
Togun 2015  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Prospective, cohort, consecutive
Patient characteristics and setting Enrolment criteria: household contact of adult smear-positive TB
cases
Age: < 15 years; median 6 years (IQR 3–9 years)
Sex: 49% female
HIV infection: 0%
Sample size included for analysis: 150
Setting: outpatient
Country: The Gambia
World Bank Income Classification: low
High TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 23.3%
Index tests Cough > 2 weeks; weight loss; BMI-for-age z-score < –2; fatigue;
night sweats; fever; CXR
Target condition and reference standard(s) Active TB not specified as pulmonary.
Togun 2016 
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Composite reference standard: microbiological diagnosis or clin-
ical diagnosis, defined as: suggestive appearance on chest radi-
ograph; and favourable response to specific antituberculosis ther-
apy or positive TST (or both) or suggestive histological appear-
ances on biopsy material
Flow and timing Index test and reference standard reported as occurring on the







Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
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Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, prospective, consecutive
Patient characteristics and setting Enrolment criteria: close contact of adult pulmonary TB cases
Age: < 15 years; median 6 years (IQR 3–10 years)
Sex: NR
HIV infection: NR
Sample size included for analysis: 265
Setting: outpatient
Country: Indonesia
World Bank Income Classification: lower middle
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 7.9%
Index tests Any 1 of: persistent cough, fever, weight loss, or failure to thrive
Target condition and reference standard(s) Active TB not specified as pulmonary.
Composite reference standard: defined as certain, probable, or
possible TB ('possible' defined as "at least one of the well-defined
symptoms and either of the following: a positive clinical response
to anti-TB treatment OR chest radiography was consistent with in-
trathoracic TB")
Flow and timing Index test and reference standard reported as occurring on the
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Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Triasih 2015a  (Continued)
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Patient Sampling Cohort, prospective, consecutive
Patient characteristics and setting Enrolment criteria: close contact of pulmonary TB cases
Age: < 15 years; median 6 years (IQR 3–10 years)
Sex: NR
HIV infection: NR
Sample size included for analysis: 265
Setting: community (household)
Country: Indonesia
World Bank Income Classification: lower middle
High TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 7.9%
Index tests CXR
Target condition and reference standard(s) Active TB: not defined as pulmonary a priori but all diagnosed cas-
es at least had pulmonary disease.
Composite reference standard: defined as certain, probable, or
possible TB (possible defined as "at least one of the well-defined
symptoms and either of the following: a positive clinical response
to anti-TB treatment OR chest radiography was consistent with in-
trathoracic TB")
Flow and timing Time between index test and reference standard not reported;
of 269 eligible participants, 265 received the index and reference
standards.
Comparative  
Notes None of the 21 children diagnosed with active TB had microbio-
logical confirmation. Chest radiographs were reviewed by 4 read-
ers, and data were only extracted for the reader with the highest




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Triasih 2015b 
Screening tests for active pulmonary tuberculosis in children (Review)










Cochrane Database of Systematic Reviews
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
No    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, prospective, consecutive
Patient characteristics and setting Enrolment criteria: household contacts of microbiologically con-
firmed paediatric TB cases
Age: < 20 years; mean 11.9 years (SD 7.9 years)
Ustero 2017 
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Sex: 62.5% female
HIV infection: 16.7%
Sample size included for analysis: 24
Setting: community (household)
Country: Eswatini
World Bank Income Classification: lower middle
High TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 4.5%
Index tests Any cough, fever, night sweats, or weight loss
Target condition and reference standard(s) Pulmonary TB, microbiological reference standard
Flow and timing Time between index test and reference standard not reported,
portion of participants with negative index test (< 10%) did not re-






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Ustero 2017  (Continued)
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Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, retrospective
Patient characteristics and setting Enrolment criteria: children and adolescents living with HIV re-
ceiving routine outpatient HIV care
Age: < 20 years; median 11.2 years (IQR 6.9–15.0 years)
Sex: 50% female
HIV infection: 100%
Sample size included for analysis: 240,161 screens on 20,706 par-
ticipants
Setting: outpatient
Country: Botswana, Eswatini, Lesotho, Malawi, Tanzania (2 sites),
Uganda
World Bank Income Classification: 'low' for Malawi, Tanzania and
Uganda; 'low-middle' for Eswatini and Lesotho; 'upper-middle' for
Botswana
High TB burden country: Lesotho, Tanzania
Vonasek 2021 
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High TB/HIV burden country: Botswana, Eswatini, Lesotho,
Malawi, Tanzania, Uganda
Prevalence of TB cases in the study: 7.7%
Index tests Children: any current fever, cough, poor weight gain, or recent TB
contact; adolescents: any current fever, cough, night sweats, or
weight loss
Target condition and reference standard(s) Target condition: active TB not specified as pulmonary.
Reference standard: composite, clinician decision based on clini-
cal signs and symptoms, radiograph imaging, and Xpert MTB/RIF
testing
Flow and timing Timing between index tests and reference standard not reported.
For those diagnosis of TB disease, only the single symptom screen
nearest the date of diagnosis was analyzed, and all other future






Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (All tests)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 3: Reference Standard
Vonasek 2021  (Continued)
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Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Unclear    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Unclear    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    
Could the patient flow have introduced bias?   High risk  
Vonasek 2021  (Continued)
BMI: body mass index; CXR: chest radiography; IQR: interquartile range; LJ: Löwenstein-Jensen; MGIT: Mycobacterium Growth Indicator
Tube; MUAC: mid-upper arm circumference; SD: standard deviation; TB: tuberculosis; TST: tuberculin skin test; WHO: World Health
Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Ackerman 2010 Ineligible study design.
Aldridge 2016 Data not available for age group of interest.
Alekseev 2018 Data not available for age group of interest.
Armstrong-Hough 2017 Diagnostic study.
Auld 2013 Ineligible study design.
Azit 2019 No eligible reference test(s).
Bamford 2010 Ineligible study design.
Basta 2010 No eligible reference test(s).
Bennet 2017 No eligible index test(s).
Bonnet 2017 No eligible reference test(s).
Bosa 2017 No eligible reference test(s).
Boullier 2017 No eligible index test(s).
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Study Reason for exclusion
Chiappini 2019 Data not available for age group of interest.
Chisti 2014 Diagnostic study.
Curtis 1999 No eligible index test(s).
David 2017 Diagnostic study.
de Lima 2013 No eligible index test(s).
Do Nascimento Maia 2016 No eligible index test(s).
Dorjee 2019 Data not available for age group of interest.
Driver 2002 No eligible index test(s).
Egere 2017 No eligible index test(s).
Faccini 2013 No eligible index test(s).
Fortunato 2011 No eligible reference test(s).
Francis 2002 No eligible index test(s).
Galli 2016 No eligible index test(s).
Gashu 2016 No eligible reference test(s).
Girardi 2007 No eligible index test(s).
Gomez-Pastrana 1999 No eligible index test(s).
Gwee 2013 Ineligible study design.
Hanrahan 2019 Ineligible study design.
Hoffman 1996 No eligible index test(s).
Huang 2016 No eligible index test(s).
Izumi 2017 No eligible index test(s).
Karki 2017 No eligible index test(s).
Kemigisha 2015 No eligible index test(s).
Kim 2017 Ineligible study design.
Kondo 2003 No eligible index test(s).
Lee 2008 No eligible index test(s).
Leung 2006 No eligible index test(s).
Li 2015 Diagnostic study.
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Study Reason for exclusion
Ling 2013 Diagnostic study.
Mahomed 2013 Data not available for age group of interest.
Malik 2018 Reference standard not applied to those with negative screens.
Marais 2006 Diagnostic study.
Marais 2009b No eligible index test(s).
Marcy 2019 Diagnostic study.
Masur 2017 No eligible reference test(s).
Minhas 2017 No eligible reference test(s).
Moran-Mendoza 2010 No eligible index test(s).
Mueller-Hermelink 2018 Ineligible study design.
Murray 2019 No eligible index test(s).
Nduba 2018 No eligible index test(s).
Ntinginya 2012 No eligible index test(s).
Oh 2018 No eligible reference test(s).
Padmapriyadarsini 2016 No eligible reference test(s).
Pan 2019 No eligible index test(s).
Penin 2007 No eligible index test(s).
Penn-Nicholson 2019 Ineligible study design.
Puryear 2013 No eligible reference test(s).
Rachow 2012 Diagnostic study.
Ramirez 2006 Diagnostic study.
Rossoni 2020 Diagnostic study.
Salinas 2002 No eligible index test(s).
Saunders 2014 No eligible index test(s).
Shah 2008 No eligible reference test(s).
Shaikh 2017 Diagnostic study.
Sollai 2017 No eligible index test(s).
Spyridis 2003 No eligible index test(s).
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Study Reason for exclusion
Swingler 2000 No eligible reference test(s).
Szkwarko 2018 No eligible index test(s).
Thee 2019 No eligible index test(s).
van Schalkwyk 2014 No eligible index test(s).
Verver 2005 No included index test(s).
Williams 2016 No eligible index test(s).
Williams 2019 No eligible index test(s).
Yang 2018 No eligible index test(s).
Yuan 1995 No eligible index test(s).
Zachariah 2003 No eligible reference test(s).
 
 
D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of participants
1 One or more of cough, fever, or poor weight gain, close tuberculosis (TB) con-
tacts, composite
4 2695
2 One or more of cough, fever, or decreased playfulness; < 5 years of age (y/o)
inpatient or outpatient, composite
3 2445
3 World Health Organization 4-symptom screen, outpatients living with HIV,
composite
2 203135
4 Chest radiograph (CXR) abnormal, close TB contacts, composite 8 3513
5 CXR suggestive, close TB contacts, composite 4 2550
6 CXR suggestive, < 5 y/o inpatient or outpatient, composite 3 2388
7 CXR abnormal, < 5 y/o hospitalized with pneumonia, microbiological 1 3540
8 Weight or body mass index (BMI) for age z-score < –2, close TB contacts, com-
posite
3 1399
9 Weight or BMI for age z-score < –2, inpatient or outpatient, composite 5 1723
10 Weight or BMI for age z-score < –2, inpatient or outpatient, microbiological 2 561
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Test No. of studies No. of participants
11 Xpert MTB/RIF, inpatient or outpatient, microbiological 2 787
12 Xpert MTB/RIF, inpatient or outpatient, composite 2 787
13 Current cough, < 15 y/o, microbiological 1 113
14 Cough > 1 week, < 5 y/o, microbiological 1 300
15 Cough > 3 weeks, < 5 y/o, microbiological 0 0
16 Cough > 3 weeks, < 15 y/o, microbiological 0 0
17 Cough > 4 weeks, < 5 y/o, microbiological 0 0
18 Cough > 4 weeks, < 15 y/o, microbiological 0 0
19 Cough > 3 weeks, < 15 y/o, and HIV+, microbiological 0 0
20 Cough > 4 weeks, < 15 y/o, and HIV+, microbiological 0 0
21 Any cough, < 15 y/o, microbiological 2 413
22 Current cough, < 5 y/o, composite 1 252
23 Current cough, < 15 y/o, composite 1 113
24 Cough > 1 week, < 5 y/o, composite 1 300
25 Cough > 2 weeks, < 15 y/o, composite 1 150
26 Any cough, < 15 y/o, composite 4 815
27 TB contact, < 5 y/o, microbiological 1 300
28 TB contact, < 15 y/o, microbiological 1 300
29 TB contact, < 20 y/o, microbiological 1 300
30 TB contact, < 15 y/o, and HIV+, microbiological 0 0
31 TB contact, < 5 y/o, composite 1 300
32 TB contact, < 20 y/o, composite 1 300
33 Current fever, < 5 y/o, microbiological 0 0
34 Current fever, < 15 y/o, microbiological 2 413
35 Fever > 1 week, < 5 y/o, microbiological 1 300
36 Fever, < 15 y/o, and HIV+, microbiological 0 0
37 Current fever, < 5 y/o, composite 2 552
38 Current fever, < 15 y/o, composite 5 973
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Test No. of studies No. of participants
39 Fever > 1 week, < 5 y/o, composite 1 300
40 Weight for height z-score < –3, < 5 y/o, microbiological 1 127
41 Weight for height z-score < –3, < 5 y/o, composite 2 1985
42 Severe malnutrition, < 5 y/o, composite 1 300
43 Severe malnutrition, < 5 y/o, microbiological 1 300
44 Weight loss or poor weight gain, < 5 y/o, microbiological 0 0
45 Weight loss or poor weight gain, < 15 y/o, microbiological 1 113
46 Weight loss or poor weight gain, < 20 y/o, microbiological 1 113
47 Weight loss or poor weight gain, < 15 y/o, and HIV+, microbiological 0 0
48 Weight loss or poor weight gain, < 5 y/o, composite 1 252
49 Weight loss or poor weight gain, < 15 y/o, composite 4 673
50 Weight loss or poor weight gain, < 20 y/o, composite 4 673
51 Fatigue or lethargy, < 5 y/o, microbiological 1 299
52 Fatigue or lethargy, < 15 y/o, microbiological 2 412
53 Fatigue or lethargy, < 15 y/o, and HIV+, microbiological 0 0
54 Fatigue or lethargy, < 5 y/o, composite 2 551
55 Fatigue or lethargy, < 15 y/o, composite 4 814
56 Fatigue or lethargy, < 20 y/o, composite 4 814
57 Night sweats, < 5 y/o, microbiological 0 0
58 Night sweats, < 15 y/o, microbiological 0 0
59 Night sweats, < 15 y/o, and HIV+, microbiological 0 0
60 Night sweats, < 15 y/o, composite 1 150
61 CXR abnormal, < 15 y/o, microbiological 1 482
62 CXR suggestive, < 5 y/o, microbiological 1 299
63 CXR suggestive, < 15 y/o, microbiological 1 299
64 CXR abnormal, < 15 y/o, composite 5 1113
65 CXR suggestive, < 15 y/o, composite 5 2850
66 Xpert MTB/Rif, < 5 y/o, microbiological 1 300
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Test No. of studies No. of participants
67 Xpert MTB/Rif, < 5 y/o, composite 1 300
68 One of multiple symptoms, < 5 y/o, microbiological 1 235
69 One of multiple symptoms, < 15 y/o, microbiological 3 740
70 One of multiple symptoms, < 20 y/o, microbiological 3 744
71 One of multiple symptoms, < 5 y/o, composite 4 2553
72 One of multiple symptoms, < 15 y/o, composite 7 4760
73 One of multiple symptoms, < 20 y/o, composite 7 4760
74 Any cough, < 15 y/o, contact tracing, composite 2 402
75 Current fever, < 15 y/o, contact tracing, composite 3 560
76 Weight loss or poor weight gain, < 20 y/o, contact tracing, composite 3 560
77 CXR abnormal, < 15 y/o, contact tracing, composite 4 963
78 CXR suggestive, < 5 y/o, contact tracing, composite 2 2089
79 One of multiple symptoms, < 15 y/o, contact tracing, composite 5 3182
80 TB contact, < 20 y/o in inpatient or outpatient settings, microbiological 1 300
81 Weight loss or poor weight gain, < 20 y/o in inpatient or outpatient settings,
microbiological
1 113
82 One of multiple symptoms, < 20 y/o in inpatient or outpatient settings, mi-
crobiological
2 722
83 Weight loss or poor weight gain, < 20 y/o in inpatient or outpatient settings,
composite
4 673
84 Fatigue or lethargy, < 20 y/o in inpatient or outpatient settings, composite 4 814
85 CXR abnormal, < 15 y/o, contact tracing, composite 4 963
86 One of multiple symptoms, < 15 y/o in inpatient or outpatient settings,
composite
7 4760
87 Mid-upper arm circumference (MUAC) < 11.5 cm, < 5 y/o, microbiological 1 300
88 MUAC < 11.5 cm, < 5 y/o, composite 1 300
89 CXR abnormal, < 15 y/o in community, composite 1 265
90 One of cough, fever, or decreased playfulness; < 15 y/o in inpatient or out-
patient settings, composite
4 2661
91 One of cough, fever, or decreased playfulness; < 15 y/o, contact tracing,
composite
3 2426
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Test 1.   One or more of cough, fever, or poor weight gain, close tuberculosis (TB) contacts, composite
 
 
Test 2.   One or more of cough, fever, or decreased playfulness;
< 5 years of age (y/o) inpatient or outpatient, composite
 
 
Test 3.   World Health Organization 4-symptom screen, outpatients living with HIV, composite
 
 
Test 4.   Chest radiograph (CXR) abnormal, close TB contacts, composite
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Test 5.   CXR suggestive, close TB contacts, composite
 
 
Test 6.   CXR suggestive, < 5 y/o inpatient or outpatient, composite
 
 
Test 7.   CXR abnormal, < 5 y/o hospitalized with pneumonia, microbiological
 
 
Test 8.   Weight or body mass index (BMI) for age z-score < –2, close TB contacts, composite
 
 
Test 9.   Weight or BMI for age z-score < –2, inpatient or outpatient, composite
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Test 10.   Weight or BMI for age z-score < –2, inpatient or outpatient, microbiological
 
 
Test 11.   Xpert MTB/RIF, inpatient or outpatient, microbiological
 
 
Test 12.   Xpert MTB/RIF, inpatient or outpatient, composite
 
 
Test 13.   Current cough, < 15 y/o, microbiological
 
 
Test 14.   Cough > 1 week, < 5 y/o, microbiological
 
 
Test 15.   Cough > 3 weeks, < 5 y/o, microbiological
 
 
Screening tests for active pulmonary tuberculosis in children (Review)










Cochrane Database of Systematic Reviews
Test 16.   Cough > 3 weeks, < 15 y/o, microbiological
 
 
Test 17.   Cough > 4 weeks, < 5 y/o, microbiological
 
 
Test 18.   Cough > 4 weeks, < 15 y/o, microbiological
 
 
Test 19.   Cough > 3 weeks, < 15 y/o, and HIV+, microbiological
 
 
Test 20.   Cough > 4 weeks, < 15 y/o, and HIV+, microbiological
 
 
Test 21.   Any cough, < 15 y/o, microbiological
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Test 22.   Current cough, < 5 y/o, composite
 
 
Test 23.   Current cough, < 15 y/o, composite
 
 
Test 24.   Cough > 1 week, < 5 y/o, composite
 
 
Test 25.   Cough > 2 weeks, < 15 y/o, composite
 
 
Test 26.   Any cough, < 15 y/o, composite
 
 
Test 27.   TB contact, < 5 y/o, microbiological
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Test 28.   TB contact, < 15 y/o, microbiological
 
 
Test 29.   TB contact, < 20 y/o, microbiological
 
 
Test 30.   TB contact, < 15 y/o, and HIV+, microbiological
 
 
Test 31.   TB contact, < 5 y/o, composite
 
 
Test 32.   TB contact, < 20 y/o, composite
 
 
Test 33.   Current fever, < 5 y/o, microbiological
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Test 34.   Current fever, < 15 y/o, microbiological
 
 
Test 35.   Fever > 1 week, < 5 y/o, microbiological
 
 
Test 36.   Fever, < 15 y/o, and HIV+, microbiological
 
 
Test 37.   Current fever, < 5 y/o, composite
 
 
Test 38.   Current fever, < 15 y/o, composite
 
 
Test 39.   Fever > 1 week, < 5 y/o, composite
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Test 40.   Weight for height z-score < –3, < 5 y/o, microbiological
 
 
Test 41.   Weight for height z-score < –3, < 5 y/o, composite
 
 
Test 42.   Severe malnutrition, < 5 y/o, composite
 
 
Test 43.   Severe malnutrition, < 5 y/o, microbiological
 
 
Test 44.   Weight loss or poor weight gain, < 5 y/o, microbiological
 
 
Test 45.   Weight loss or poor weight gain, < 15 y/o, microbiological
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Test 46.   Weight loss or poor weight gain, < 20 y/o, microbiological
 
 
Test 47.   Weight loss or poor weight gain, < 15 y/o, and HIV+, microbiological
 
 
Test 48.   Weight loss or poor weight gain, < 5 y/o, composite
 
 
Test 49.   Weight loss or poor weight gain, < 15 y/o, composite
 
 
Test 50.   Weight loss or poor weight gain, < 20 y/o, composite
 
 
Test 51.   Fatigue or lethargy, < 5 y/o, microbiological
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Test 52.   Fatigue or lethargy, < 15 y/o, microbiological
 
 
Test 53.   Fatigue or lethargy, < 15 y/o, and HIV+, microbiological
 
 
Test 54.   Fatigue or lethargy, < 5 y/o, composite
 
 
Test 55.   Fatigue or lethargy, < 15 y/o, composite
 
 
Test 56.   Fatigue or lethargy, < 20 y/o, composite
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Test 57.   Night sweats, < 5 y/o, microbiological
 
 
Test 58.   Night sweats, < 15 y/o, microbiological
 
 
Test 59.   Night sweats, < 15 y/o, and HIV+, microbiological
 
 
Test 60.   Night sweats, < 15 y/o, composite
 
 
Test 61.   CXR abnormal, < 15 y/o, microbiological
 
 
Test 62.   CXR suggestive, < 5 y/o, microbiological
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Test 63.   CXR suggestive, < 15 y/o, microbiological
 
 
Test 64.   CXR abnormal, < 15 y/o, composite
 
 
Test 65.   CXR suggestive, < 15 y/o, composite
 
 
Test 66.   Xpert MTB/Rif, < 5 y/o, microbiological
 
 
Test 67.   Xpert MTB/Rif, < 5 y/o, composite
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Test 68.   One of multiple symptoms, < 5 y/o, microbiological
 
 
Test 69.   One of multiple symptoms, < 15 y/o, microbiological
 
 
Test 70.   One of multiple symptoms, < 20 y/o, microbiological
 
 
Test 71.   One of multiple symptoms, < 5 y/o, composite
 
 
Test 72.   One of multiple symptoms, < 15 y/o, composite
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Test 73.   One of multiple symptoms, < 20 y/o, composite
 
 
Test 74.   Any cough, < 15 y/o, contact tracing, composite
 
 
Test 75.   Current fever, < 15 y/o, contact tracing, composite
 
 
Test 76.   Weight loss or poor weight gain, < 20 y/o, contact tracing, composite
 
 
Test 77.   CXR abnormal, < 15 y/o, contact tracing, composite
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Test 78.   CXR suggestive, < 5 y/o, contact tracing, composite
 
 
Test 79.   One of multiple symptoms, < 15 y/o, contact tracing, composite
 
 
Test 80.   TB contact, < 20 y/o in inpatient or outpatient settings, microbiological
 
 
Test 81.   Weight loss or poor weight gain, < 20 y/o in inpatient or outpatient settings, microbiological
 
 
Test 82.   One of multiple symptoms, < 20 y/o in inpatient or outpatient settings, microbiological
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Test 83.   Weight loss or poor weight gain, < 20 y/o in inpatient or outpatient settings, composite
 
 
Test 84.   Fatigue or lethargy, < 20 y/o in inpatient or outpatient settings, composite
 
 
Test 85.   CXR abnormal, < 15 y/o, contact tracing, composite
 
 
Test 86.   One of multiple symptoms, < 15 y/o in inpatient or outpatient settings, composite
 
 
Test 87.   Mid-upper arm circumference (MUAC) < 11.5 cm, < 5 y/o, microbiological
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Test 88.   MUAC < 11.5 cm, < 5 y/o, composite
 
 
Test 89.   CXR abnormal, < 15 y/o in community, composite
 
 
Test 90.   One of cough, fever, or decreased playfulness; < 15 y/o in inpatient or outpatient settings, composite
 
 
Test 91.   One of cough, fever, or decreased playfulness; < 15 y/o, contact tracing, composite
 
 
A D D I T I O N A L   T A B L E S
 
Study Country or countries of sampling Sampling in TB high-bur-
den country?a
Aggerbeck 2018 South Africa Yes
Birungi 2018 Rwanda No
Clemente 2017 Italy No
Dreesman 2017 Belgium No
Jaganath 2013 Uganda No
Table 1.   Summary of included studies 
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Kruk 2008 South Africa Yes
LaCourse 2014 b Malawi No
PERCH 2019 b Bangladesh, The Gambia, Kenya, Mali, South Africa, Thai-
land, and Zambia
Majority
Portevin 2014 Tanzania Yes
Rose 2012 Tanzania Yes
Sawry 2018 b South Africa Yes
Schwoebel 2020 b Benin, Burkina Faso, Cameroon, and CAR Only 1 of 4 countries (CAR)
Tieu 2014 Thailand Yes
Togun 2015 b The Gambia No
Togun 2016 The Gambia No
Triasih 2015a Indonesia Yes
Triasih 2015b b Indonesia Yes
Ustero 2017 Eswatini (Swaziland) Yes
Vonasek 2021 b Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Ugan-
da
2 of 6 countries
Publication year range: 2008 to 2021 Africa: 14 studies
Asia: 4 studies
Europe: 2 studies
Sampling at least par-
tially in TB high-burden
countries: 12 studies
Table 1.   Summary of included studies  (Continued)
CAR: Central African Republic, TB: tuberculosis.
aTB high-burden countries are defined in the WHO Global Tuberculosis Report 2020.
bStudies not captured through database searching but identified through contacting the community of TB experts. All other studies
identified through database searching.
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Close TB contacts ≥ 1 of cough, fever, or
poor weight gain
CRS 4 2% to 13% 2695 (113) 89% (52% to 98%) 69% (51% to 83%)
Inpatient or outpatient set-
tings, < 5 years
≥ 1 of cough, fever, or
decreased playfulness
CRS 3 (3)% to 13% 2445 (106) 64% to 76%a 37% to 77%a
Outpatients living with HIV ≥ 1 of cough, fever,
poor weight gain, or




CRS 2 3% and 8% 203,135
(1219)b
61% (58% to 64%) 94% (86% to 98%)
Close TB contacts Undernutrition CRS 3 10% to 13% 1399 (162) 21% (11% to 38%) 85% (71% to 93%)
Inpatient or outpatient set-
tings
Undernutrition CRS 5 10% to 34% 1723 (233) 32% (18% to 50%) 75% (56% to 88%)
Inpatient or outpatient set-
tings
Undernutrition MRS 2 4% and 16% 561 (39) 48% (26% to 70%)
and 67% (41% to
87%)
62% (49% to 74%)
and 72% (68% to
76%)
Close TB contacts Abnormal CXR CRS 8 2% to 25% 3513 (232) 87% (75% to 93%) 99% (68% to 100%)
Close TB contacts Suggestive CXR CRS 4 2% to 13% 2550 (113) 84% (70% to 92%) 91% (90% to 92%)
Inpatient or outpatient set-
tings, < 5 years
Suggestive CXR CRS 3 2% to 13% 2388 (110) 87% (66% to 96%) 89% (88% to 90%)
Inpatients with pneumonia, <
5 years
Abnormal CXR MRS 1 1% 3540 (28) 86% (67% to 96%) 56% (54% to 58%)
Inpatient or outpatient set-
tings
Xpert MTB/RIF MRS 2 1% and 4% 787 (16) 43% (18% to 71%)
and 100% (16% to
100%)
99% (97% to 100%)
and 100% (98% to
100%)
Inpatient or outpatient set-
tings
Xpert MTB/RIF CRS 2 7% and 13% 787 (84) 9% (1% to 29%)











































































































































































CI: confidence interval; CRS: composite reference standard; CXR: chest radiography; MRS: microbiological reference standard; TB: tuberculosis; WHO: World Health Organization.
aReported as range from studies as meta-analysis did not converge and pooled estimates could not be obtained.

















































































Threshold for a positive test








2 NR Any of these features, at the same location,
detected by both interpreters: air compres-
sion or tracheal displacement, soQ tissue
density suggestive of lymphadenopathy, air
space opacification, bilateral nodule picture
(military or larger widespread), pleural ef-




NR NR NR NR Hilar lymphadenopathy, pleurisy, pneumo-
nia with calcifications, miliary pattern
Dreesman
2017
NR NR NR NR Suggestive of active tuberculosis
Kruk 2008 AP and lateral NR 2 NR Lymph node disease, airway compression,
lung cavitation, pleural effusion, or miliary
pattern
LaCourse 2014 AP and lateral NR 2 NR Chest radiography consistent with tubercu-
losis
PERCH 2019 NR Trained radi-
ologists and
paediatricians




AP only Medical doc-
tor
1 NA Suggestive of tuberculosis
Tieu 2014 NR NR NR NR Hilar, interstitial, or other types of lung infil-
trates, other infiltrates; and lymph node dis-
ease
Togun 2016 NR Study physi-
cians
2 NR Abnormality consistent with active tubercu-
losis disease
Triasih 2015b AP and lateral 2 paediatri-
cians and 2 ra-
diologists
4 k = 0.25–0.46 Hilar lymphadenopathy, parenchymal infil-
trate or consolidation, pleural effusion, mil-
iary pattern, Gohn focus, calcification
Table 3.   Chest radiography details by study 
AP: anteroposterior view; k: kappa statistic; NA: not applicable; NR: not reported.
 
 
A P P E N D I C E S
Appendix 1. Search strategy
MEDLINE (OVID)
1 exp child/ or exp infant/
2 (newborn* or new-born* or neonat* or neo-nat* or infancy* or infant* or baby* or babies* or toddler*).ti,ab,kw.
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3 (child* or children* or boy or boys or girl* or youth* or pediatric* or paediatric* or kid or kids or "school-age*" or juvenile* or preteen*
or tween*).ti,ab,kw.
4 (preteen* or pre-teen* or fiQeen* or fourteen* or thirteen* or teen* or adolescen* or preadolescen* or "pre-adolescen*" or pubescen* or
prepubescen* or "pre-pubescen*").ti,ab,kw.
5 1 or 2 or 3 or 4
6 exp Mycobacterium tuberculosis/
7 exp Tuberculosis/
8 (tuberculos* or tb*).ti,ab,kw.
9 6 or 7 or 8
10 ((active* or symptomatic*) adj3 (tuberculosis* or tb*)).ti,ab,kw.
11 ("active tuberculos*" or "active tb*").kw.
12 ("symptomatic* tuberculos*" or "symptomatic* tb*").kw.
13 10 or 11 or 12
14 9 and 13
15 exp Symptom Assessment/ or exp symptom flare up/
16 (symptom* or manifest*).ti,ab,kw.




21 (hemoptysis* or "hemo-ptysis*").ti,ab,kw.
22 (cough* adj3 blood*).ti,ab,kw.
23 ("blood* cough*" or "cough* blood*").kw.
24 Fever/
25 (fever* or "high* temp*").ti,ab,kw.
26 Weight Loss/
27 ("weight loss*" or weightloss*).ti,ab,kw.
28 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29 17 and 28
Embase
1 juvenile'/de OR 'child'/exp
2 newborn*:ti,ab,kw OR 'new born*':ti,ab,kw OR neonat*:ti,ab,kw OR 'neo nat*':ti,ab,kw OR infancy*:ti,ab,kw OR infant*:ti,ab,kw OR
baby*:ti,ab,kw OR babies*:ti,ab,kw OR toddler*:ti,ab,kw
3 child*:ti,ab,kw OR children*:ti,ab,kw OR boy:ti,ab,kw OR boys:ti,ab,kw OR girl*:ti,ab,kw OR youth*:ti,ab,kw OR pediatric*:ti,ab,kw
OR paediatric*:ti,ab,kw OR kid:ti,ab,kw OR kids:ti,ab,kw OR 'school-age*':ti,ab,kw OR juvenile*:ti,ab,kw OR preteen*:ti,ab,kw OR
tween*:ti,ab,kw
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4 preteen*:ti,ab,kw OR 'pre teen*':ti,ab,kw OR fiQeen*:ti,ab,kw OR fourteen*:ti,ab,kw OR thirteen*:ti,ab,kw OR teen*:ti,ab,kw OR
adolescen*:ti,ab,kw OR preadolescen*:ti,ab,kw OR 'pre-adolescen*':ti,ab,kw OR pubescen*:ti,ab,kw OR prepubescen*:ti,ab,kw OR 'pre-
pubescen*':ti,ab,kw
5 #1 OR #2 OR #3 OR #4
6 mycobacterium tuberculosis'/exp
7 tuberculosis'/exp
8 tuberculos*:ti,ab,kw OR tb:ti,ab,kw
9 #6 OR #7 OR #8
10 ((active* OR symptomatic*) NEAR/3 (tuberculosis* OR tb)):ti,ab,kw
11 #9 AND #10
12 symptom'/exp
13 symptom*:ti,ab,kw OR manifest*:ti,ab,kw




18 hemoptysis*:ti,ab,kw OR 'hemo-ptysis*':ti,ab,kw
19 (cough* NEAR/3 blood*):ti,ab,kw
20 fever'/exp
21 fever*:ti,ab,kw OR 'high* temp*':ti,ab,kw
22 body weight loss'/de
23 weight loss*':ti,ab,kw OR weightloss*:ti,ab,kw
24 #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23
25 #14 AND #24
26 thorax radiography'/exp
27 ((chest* OR lung* OR thoracic*) NEAR/3 ('x-ray*' OR xray* OR radiogra* OR imag*)):ti,ab,kw
28 tuberculin test'/exp
29 tubercul* skin test*':ti,ab,kw OR tst:ti,ab,kw OR 'tubercul* test*':ti,ab,kw OR 'tb skin test*':ti,ab,kw OR 'tb test*':ti,ab,kw
SCOPUS
1 TITLE-ABS-KEY ( newborn* OR new-born* OR neonat* OR neo-nat* OR infancy* OR infant* OR baby* OR babies* OR toddler* )
2 TITLE-ABS-KEY ( child* OR children* OR boy OR boys OR girl* OR youth* OR pediatric* OR paediatric* OR kid OR kids OR "school-age*"
OR juvenile* OR preteen* OR tween* )
3 "
TITLE-ABS-KEY ( preteen* OR pre-teen* OR fiQeen* OR fourteen* OR thirteen* OR teen* OR adolescen* OR preadolescen* OR ""pre-
adolescen*"" OR pubescen* OR prepubescen* OR ""pre-pubescen*"" ) "
4 ( TITLE-ABS-KEY ( newborn* OR new-born* OR neonat* OR neo-nat* OR infancy* OR infant* OR baby* OR babies* OR toddler* ) ) OR
( TITLE-ABS-KEY ( child* OR children* OR boy OR boys OR girl* OR youth* OR pediatric* OR paediatric* OR kid OR kids OR "school-age*"
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OR juvenile* OR preteen* OR tween* ) ) OR ( TITLE-ABS-KEY ( preteen* OR pre-teen* OR fiQeen* OR fourteen* OR thirteen* OR teen* OR
adolescen* OR preadolescen* OR "pre-adolescen*" OR pubescen* OR prepubescen* OR "pre-pubescen*" ) )
5 TITLE-ABS-KEY ( tuberculos* OR tb* )
6 TITLE-ABS-KEY ( ( active* OR symptomatic* ) W/3 ( tuberculosis* OR tb* ) )
7 ( TITLE-ABS-KEY ( tuberculos* OR tb* ) ) AND ( TITLE-ABS-KEY ( ( active* OR symptomatic* ) W/3 ( tuberculosis* OR tb* ) ) )
8 TITLE-ABS-KEY ( symptom* OR manifest* )
9 TITLE-ABS-KEY ( cough* )
10 TITLE-ABS-KEY ( hemoptysis* OR "hemo-ptysis*" )
11 TITLE-ABS-KEY ( cough* W/3 blood* )
12 TITLE-ABS-KEY ( fever* OR "high* temp*" )
13 "
TITLE-ABS-KEY ( ""weight loss*"" OR weightloss* ) "
14 ( TITLE-ABS-KEY ( cough* ) ) OR ( TITLE-ABS-KEY ( hemoptysis* OR "hemo-ptysis*" ) ) OR ( TITLE-ABS-KEY ( cough* W/3 blood* ) ) OR
( TITLE-ABS-KEY ( fever* OR "high* temp*" ) ) OR ( TITLE-ABS-KEY ( "weight loss*" OR weightloss* ) )
15 ( TITLE-ABS-KEY ( symptom* OR manifest* ) ) AND ( ( TITLE-ABS-KEY ( cough* ) ) OR ( TITLE-ABS-KEY ( hemoptysis* OR "hemo-ptysis*" ) )
OR ( TITLE-ABS-KEY ( cough* W/3 blood* ) ) OR ( TITLE-ABS-KEY ( fever* OR "high* temp*" ) ) OR ( TITLE-ABS-KEY ( "weight loss*" OR
weightloss* ) ) )
16 TITLE-ABS-KEY ( ( chest* OR lung* OR thoracic* ) W/3 ( "x-ray*" OR xray* OR radiogra* OR imag* ) )
17 TITLE-ABS-KEY ( "tubercul* skin test*" OR tst OR "tb skin test*" )
18 TITLE-ABS-KEY ( ( "interferon-gamma releas*" OR "IFN-gamma releas*" ) W/3 ( test* OR assay* ) )
19 TITLE-ABS-KEY ( igra )
20 TITLE-ABS-KEY ( "QuantiFERON-TB*" OR quantiferontb* OR qQ* OR "T-Spot*" OR tspot* )
21 TITLE-ABS-KEY ( "immunologic* test*" OR "immuno-logic test*" )
22 TITLE-ABS-KEY ( "microbiologic* confirm*" OR "micro-biologic* confirm*" )
23 TITLE-ABS-KEY ( ( "Mycobacter* tubercul*" OR mtb ) W/3 ( culture* OR test* OR assay* ) )
24 TITLE-ABS-KEY ( ( tubercul* OR tb ) W/3 ( test* OR assay* ) )
25 TITLE-ABS-KEY ( ( xpert* OR genexpert* ) W/3 ( mtb OR rif OR rifampicin* OR ultra ) )
26 TITLE-ABS-KEY ( genexpert* OR xpert* )
27 TITLE-ABS-KEY ( truenat OR "True-Nat" OR trunat OR "Tru-Nat" )
28 TITLE-ABS-KEY ( "nucleic acid amplification test*" OR naat )
29 ( TITLE-ABS-KEY ( symptom* OR manifest* ) ) OR ( ( TITLE-ABS-KEY ( symptom* OR manifest* ) ) AND ( ( TITLE-ABS-KEY ( cough* ) ) OR
( TITLE-ABS-KEY ( hemoptysis* OR "hemo-ptysis*" ) ) OR ( TITLE-ABS-KEY ( cough* W/3 blood* ) ) OR ( TITLE-ABS-KEY ( fever* OR "high*
temp*" ) ) OR ( TITLE-ABS-KEY ( "weight loss*" OR weightloss* ) ) ) ) OR ( TITLE-ABS-KEY ( ( chest* OR lung* OR thoracic* ) W/3 ( "x-ray*" OR
xray* OR radiogra* OR imag* ) ) ) OR ( TITLE-ABS-KEY ( "tubercul* skin test*" OR tst OR "tb skin test*" ) ) OR ( TITLE-ABS-KEY ( ( "interferon-
gamma releas*" OR "IFN-gamma releas*" ) W/3 ( test* OR assay* ) ) ) OR ( TITLE-ABS-KEY ( igra ) ) OR ( TITLE-ABS-KEY ( "QuantiFERON-
TB*" OR quantiferontb* OR qQ* OR "T-Spot*" OR tspot* ) ) OR ( TITLE-ABS-KEY ( "immunologic* test*" OR "immuno-logic test*" ) ) OR #
23 OR ( TITLE-ABS-KEY ( ( "Mycobacter* tubercul*" OR mtb ) W/3 ( culture* OR test* OR assay* ) ) ) OR ( TITLE-ABS-KEY ( ( tubercul* OR
tb ) W/3 ( test* OR assay* ) ) ) OR ( TITLE-ABS-KEY ( ( xpert* OR genexpert* ) W/3 ( mtb OR rif OR rifampicin* OR ultra ) ) ) OR ( TITLE-ABS-
KEY ( genexpert* OR xpert* ) ) OR ( TITLE-ABS-KEY ( truenat OR "True-Nat" OR trunat OR "Tru-Nat" ) ) OR ( TITLE-ABS-KEY ( "nucleic acid
amplification test*" OR naat ) )
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30 ( ( TITLE-ABS-KEY ( newborn* OR new-born* OR neonat* OR neo-nat* OR infancy* OR infant* OR baby* OR babies* OR toddler* ) )
OR ( TITLE-ABS-KEY ( child* OR children* OR boy OR boys OR girl* OR youth* OR pediatric* OR paediatric* OR kid OR kids OR "school-
age*" OR juvenile* OR preteen* OR tween* ) ) OR ( TITLE-ABS-KEY ( preteen* OR pre-teen* OR fiQeen* OR fourteen* OR thirteen* OR teen*
OR adolescen* OR preadolescen* OR "pre-adolescen*" OR pubescen* OR prepubescen* OR "pre-pubescen*" ) ) ) AND ( ( TITLE-ABS-KEY
( tuberculos* OR tb* ) ) AND ( TITLE-ABS-KEY ( ( active* OR symptomatic* ) W/3 ( tuberculosis* OR tb* ) ) ) ) AND ( ( TITLE-ABS-KEY ( symptom*
OR manifest* ) ) OR ( ( TITLE-ABS-KEY ( symptom* OR manifest* ) ) AND ( ( TITLE-ABS-KEY ( cough* ) ) OR ( TITLE-ABS-KEY ( hemoptysis* OR
"hemo-ptysis*" ) ) OR ( TITLE-ABS-KEY ( cough* W/3 blood* ) ) OR ( TITLE-ABS-KEY ( fever* OR "high* temp*" ) ) OR ( TITLE-ABS-KEY ( "weight
loss*" OR weightloss* ) ) ) ) OR ( TITLE-ABS-KEY ( ( chest* OR lung* OR thoracic* ) W/3 ( "x-ray*" OR xray* OR radiogra* OR imag* ) ) ) OR
( TITLE-ABS-KEY ( "tubercul* skin test*" OR tst OR "tb skin test*" ) ) OR ( TITLE-ABS-KEY ( ( "interferon-gamma releas*" OR "IFN-gamma
releas*" ) W/3 ( test* OR assay* ) ) ) OR ( TITLE-ABS-KEY ( igra ) ) OR ( TITLE-ABS-KEY ( "QuantiFERON-TB*" OR quantiferontb* OR qQ* OR "T-
Spot*" OR tspot* ) ) OR ( TITLE-ABS-KEY ( "immunologic* test*" OR "immuno-logic test*" ) ) OR # 23 OR ( TITLE-ABS-KEY ( ( "Mycobacter*
tubercul*" OR mtb ) W/3 ( culture* OR test* OR assay* ) ) ) OR ( TITLE-ABS-KEY ( ( tubercul* OR tb ) W/3 ( test* OR assay* ) ) ) OR ( TITLE-ABS-
KEY ( ( xpert* OR genexpert* ) W/3 ( mtb OR rif OR rifampicin* OR ultra ) ) ) OR ( TITLE-ABS-KEY ( genexpert* OR xpert* ) ) OR ( TITLE-ABS-
KEY ( truenat OR "True-Nat" OR trunat OR "Tru-Nat" ) ) OR ( TITLE-ABS-KEY ( "nucleic acid amplification test*" OR naat ) ) )
Cochrane Library issue 2 of 12, February 2021
1 MeSH descriptor: [Child] explode all trees
2 MeSH descriptor: [Infant] explode all trees
3 (newborn* or new-born* or neonat* or neo-nat* or infancy* or infant* or baby* or babies* or toddler*):ti,ab,kw
4 (child* or children* or boy or boys or girl* or youth* or pediatric* or paediatric* or kid or kids or "school-age*" or juvenile* or preteen*
or tween*):ti,ab,kw
5 (preteen* or pre-teen* or fiQeen* or fourteen* or thirteen* or teen* or adolescen* or preadolescen* or "pre-adolescen*" or pubescen* or
prepubescen* or "pre-pubescen*"):ti,ab,kw
6 #1 or #2 or #3 or #4 or #5
7 MeSH descriptor: [Mycobacterium tuberculosis] explode all trees
8 MeSH descriptor: [Tuberculosis] explode all trees
9 (tuberculos* or tb*):ti,ab,kw
10 #7 or #8 or #9
11 (active* or symptomatic*) NEAR/3 (tuberculosis* or tb*)):ti,ab,kw
12 #10 and #11
13 MeSH descriptor: [Symptom Assessment] explode all trees
14 MeSH descriptor: [Symptom Flare Up] explode all trees
15 (symptom* or manifest*):ti,ab,kw
16 #13 or #14 or #15
17 MeSH descriptor: [Cough] explode all trees
18 (cough*):ti,ab,kw
19 MeSH descriptor: [Hemoptysis] explode all trees
20 (hemoptysis* or "hemo-ptysis*"):ti,ab,kw
21 (cough* NEAR/3 blood*):ti,ab,kw
22 MeSH descriptor: [Fever] explode all trees
23 (fever* or "high* temp*"):ti,ab,kw
24 MeSH descriptor: [Weight Loss] explode all trees
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25 ("weight loss*" or weightloss*):ti,ab,kw"
26 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
27 #16 and #26
28 MeSH descriptor: [Radiography, Thoracic] explode all trees
29 ((chest* or lung* or thoracic*) NEAR/3 ("x-ray*" or xray* or radiogra* or imag*)):ti,ab,kw
29 tubercul* skin test*':ti,ab,kw OR tst:ti,ab,kw OR 'tubercul* test*':ti,ab,kw OR 'tb skin test*':ti,ab,kw OR 'tb test*':ti,ab,kw
30 interferon gamma release assay'/exp
31 (('interferon-gamma releas*' OR 'ifn-gamma releas*') NEAR/3 (test* OR assay)):ti,ab,kw
32 igra:ti,ab,kw
33 mycobacterium tuberculosis test kit'/exp
34 (('mycobacter* tubercul*' OR mtb) NEAR/3 (culture* OR test* OR assay*)):ti,ab,kw
35 ((tubercul* OR tb) NEAR/3 (test* OR assay*)):ti,ab,kw
36 quantiferon-tb*':ti,ab,kw OR quantiferontb*:ti,ab,kw OR qQ*:ti,ab,kw OR 't-spot*':ti,ab,kw OR tspot*:ti,ab,kw
37 immunologic* test*':ti,ab,kw OR 'immuno-logic test*':ti,ab,kw
38 microbiologic* confirm*':ti,ab,kw OR 'micro-biologic* confirm*':ti,ab,kw
39 ((xpert* OR genexpert*) NEAR/3 (mtb OR rif OR rifampicin* OR ultra)):ti,ab,kw
40 genexpert*:ti,ab,kw OR xpert*:ti,ab,kw
41 truenat:ti,ab,kw OR 'true-nat':ti,ab,kw OR trunat:ti,ab,kw OR 'tru-nat':ti,ab,kw
42 nucleic acid amplification test*':ti,ab,kw OR naat:ti,ab,kw
43 #14 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42
44 #5 AND #11 AND #43
Appendix 2. QUADAS-2 review-specific guidance
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: was a consecutive or random sample of patients enrolled?
• Yes: if the study enrolled a consecutive or random sample of eligible participants.
• No: if the study selected participants by convenience.
• Unclear: if the study did not report the manner of participant selection or we could not determine.
Signalling question 2: did the study avoid inappropriate exclusions? Examples of inappropriate exclusions may have included children with
distant history of tuberculosis, children experiencing severe signs and symptoms of tuberculosis, or children with negative screening test.
• Yes: if no study participants were excluded aQer inclusion.
• No: if study participants were excluded.
• Unclear: if we could not determine.
Applicability: are there concerns that the included participants and setting do not match the review question?
Based upon the inclusion criteria, included studies focused primarily on pulmonary tuberculosis. Therefore, all included studies assessed
as 'low concern.'
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Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Symptom screen, chest radiography, and Xpert MTB/RIF and Xpert Ultra
Signalling question 1: were the index test results interpreted without knowledge of the results of the reference standard?
• Yes: if the screening test was performed without knowing whether the person had active tuberculosis. Also, with respect to Xpert MTB/
RIF and Xpert Ultra, the test results are automatically generated and the user is provided with printable test results. Thus, there is no
room for subjective interpretation of test results.
• No: if symptom questions were asked aQer the results of the reference test were known, or the chest radiograph was interpreted with
knowledge of the results of the reference test.
• Unclear: if we could not determine. For example, if it was unclear whether the chest radiograph reader was blinded to the results of
the reference standard.
Signalling question 2: if a threshold was used, was it prespecified?
For tuberculosis symptoms
This question was not applicable.
For chest radiography
• Yes: if the study clearly reported positivity criteria for abnormalities suggestive of tuberculosis or other abnormalities.
• No: if the study did not report the positivity criteria for abnormalities suggestive of tuberculosis or other abnormalities.
• Unclear: if we could not determine.
For Xpert MTB/RIF and Xpert Ultra
The threshold is prespecified in all versions of Xpert.
• Yes: for all studies using Xpert MTB/RIF or Xpert Ultra as the index test.
Applicability: are there concerns that the index test, its conduct, or its interpretation diRer from the review question?
• High concern: if the index tests were used for diagnosis rather than for screening.
• Low concern: if the index tests were performed with the intention to screen.
• Unclear concern: if we could not determine.
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: is the reference standard likely to correctly classify the target condition?
• Yes: for all studies using either a microbiological reference standard (i.e. culture, Xpert MTB/RIF, or Xpert Ultra) or a composite reference
standard as described in Reference standards. These are the acceptable reference tests for inclusion of studies in the review.
• Given the criteria for including studies in this review, all included studies had a 'yes' response.
Signalling question 2: were the reference standard results interpreted without knowledge of the results of the index test?
• Yes: if the reference test provided an automated result (e.g. MGIT 960), blinding was explicitly stated, or it was clear that the reference
standard was performed at a separate laboratory or performed by diRerent people, or both.
• No: if the study stated that the reference standard result was interpreted with knowledge of the index test result.
• Unclear: if we could not determine. We also answered unclear if the study used a composite reference standard in which the index test
was one of the components of the reference standard. In the latter situation, the study may have had incorporation bias where there
could not be blinding of the reference standard to the index test. Incorporation of the index test in the reference standard may increase
the amount of agreement between the index test results and reference standard thereby overestimating diagnostic accuracy.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
• High concern: if more than 50% of tuberculosis cases identified in the study did not have microbiologically confirmed tuberculosis.
• Low concern: if the children with tuberculosis in the study had signs and symptoms or chest radiograph abnormalities in addition to
a positive culture or Xpert result.
• Unclear concern: if we could not determine.
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Domain 4: flow and timing
Risk of bias: could the patient flow have introduced bias?
1. Was there an appropriate interval between the index test and reference standard?
• Yes: if the screening test and reference standard were applied (or specimens obtained) at the same time or within one week.
• No: if the time between the screening test and reference standard (specimen collection) was more than one week.
• Unclear: if insuRicient information was provided to decide.
2. Did all participants receive the same reference standard?
• Yes: if all participants were evaluated with the reference standard, and if all or most participants were evaluated with the same test(s).
• No: if not all participants were evaluated with the reference standard, or participants received diRerent number of reference tests.
• Unclear: if insuRicient information was provided to decide.
3. Were all participants included in the analysis?
• Yes: if all participants were included.
• No: if participants who participated were excluded, for example, cultures were lost or because they did not provide sputum for a
reference test.
• Unclear: if insuRicient information was provided to decide.
Judgements for 'risk of bias' assessments for a given domain.
• If we answered all signalling questions for a domain 'yes,' then we judged risk of bias as 'low.'
• If we answered all or most signalling questions for a domain 'no,' then we judged risk of bias as 'high.'
• If we answered only one signalling question for a domain 'no,' we discussed further the risk of bias judgement.
• If we answered all or most signalling questions for a domain 'unclear,' then we judged risk of bias as 'unclear.'
• If we answered only one signalling question for a domain 'unclear,' we discussed further the risk of bias judgement for the domain.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We made the following changes from the review protocol (Vonasek 2020).
Assessment of type and number of chest radiography interpreters as a potential source of heterogeneity was added to Secondary objectives
and noted in Investigations of heterogeneity.
We clarified in Types of studies that we excluded studies evaluating the index tests for extrapulmonary tuberculosis and studies where more
than 25% of participants with active tuberculosis had extrapulmonary disease. Hence, included studies focused primarily on pulmonary
tuberculosis.
In QUADAS-2, applicability for the reference standard was no longer determined by the proportion of those diagnosed clinically versus
microbiologically as stated in the protocol. Therefore, we assessed all included studies as 'low concern' for reference standard applicability.
In Types of studies, we removed inclusion of studies that did not apply the reference standard to participants screening negative. We
attempted to assess these types of studies, including only those with strict design criteria. However, given that only a small number of
studies would be included under this criterion and those studies included heterogeneous populations, we decided not to analyse them in
this review. Only calculation of positive predictive value would be feasible with these data, and sensitivity and specificity were the focus
of this review.
As described in Participants, we modified the inclusion criteria for studies to allow for inclusion of participants between 15 and 19 years of
age, but requiring that at least 75% of participants in any single included study were less than 15 years of age.
In Target conditions and Sensitivity analyses, we removed mention of performing sensitivity analysis for those studies that explicitly
evaluated the index tests for pulmonary tuberculosis. This sensitivity analysis was not conducted because most included studies did not
clearly describe explicit evaluation of only pulmonary tuberculosis.
As described in Statistical analysis and data synthesis, we developed symptom groups for meta-analysis of similar composite symptom
screens.
In Statistical analysis and data synthesis, we removed mention of performing test comparisons because these were not done due to limited
data.
In 'Assessment of certainty of the evidence', we explained that prespecified analyses were not performed owing to limited data.
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